POLYMERIC EXCIPIENTS FOR DRUG ADMINISTRATION APPLICATIONS.

Abstract

This disclosure relates to the field of polymer chemistry and more particularly to multiblock copolymers comprising a poly(sarcosine) block and a mixed D,L-poly(amino acid) block and uses thereof

Description

POLYMERIC EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS Field of dissemination This disclosure is directed to the field of polymer chemistry and more particularly to multiblock poly(amino acid) copolymers and their uses. Background to the disclosure Polymer excipients are commonly used in the formulation of active pharmaceutical ingredients (APIs). These polymers are used to aid in tablet dissolution, to provide a binder, or to modify the viscosity of an oral formulation. In some cases, polymer excipients are used to increase the water solubility of hydrophobic APIs. Poly(ethylene glycol) (PEG), poly(lactic acid) (PLA), poly(lactic acid-co-glycolic acid) (PLGA), and cyclodextrins (CD) are non-limiting examples of polymer excipients routinely used in drug development to improve the solubility of hydrophobic APIs. However, few options remain when these compound excipients do not adequately solubilize the hydrophobic drug.In such cases, the API may be chemically modified to increase its water solubility (e.g., prodrug or creation of a new API, such as a polymer-drug conjugate), the compound may be abandoned, or a new, non-compounded excipient may be developed. Frequently, these new excipients are custom-designed for the API of interest. This is evidenced by many drug delivery technologies developed by academic groups that solubilize specific APIs. Unless the new pharmaceutical product advances to the commercial stage, the public knows little about the synthesis, toxicity, and utility of these solubility-enhancing excipients. Accordingly, and without wishing to link to any particular theory, it would be desirable to develop a polymeric excipient that has broad utility in solubilizing a wide range of hydrophobic APIs. Such an excipient would need to encapsulate high-log P, amorphous compounds (colloquially referred to as “fat balls”) as well as highly crystalline hydrophobic APIs (colloquially referred to as “brick dust”). Polymer micelles represent a method for solubilizing hydrophobic compounds. Polymer micelles are formed by the thermodynamic self-assembly of amphiphilic block copolymers into a core-shell type structure (see: Yu, K. et al. Macromolecules 1996, 29(19), 6359; Rósler, A. et al. Adv. Drug Deliv. Rev. 2012, 64, 270). For a polymer micelle in aqueous solution, the hydrophilic block of the polymer forms the micelle crown, while the hydrophobic block forms the core. If micelle formation occurs in the presence of an additional hydrophobic molecule (e.g., a hydrophobic drug), the hydrophobic compound will spontaneously migrate to and be sequestered within the hydrophobic core of the polymer micelle. The hydrophobic drug is made soluble in water by the hydrophilic crown of the polymer micelle.It is important to note that in this particular application, the drug is physically trapped and not chemically bound to the polymer chain. A large number of amphiphilic block copolymers for drug delivery applications have been reported in the literature (see: Kedar, U. et al. Nanomedicine 2010, 6(6), 714; Ahmad, Z. et al. RSC Adv. 2014, 33, 17028; Kataoka, K. et al. Adv. Drug Delivery Rev. 2001, 47(1), 113). PEG-PLGA, PEG-PLA, PEG-poly(amino)s, poly(acrylate)-WoQue-poly(methacrylate), and derivatives thereof are all common polymers that have been investigated for polymer micelle-based drug delivery applications. A large majority of these polymers include PEG as the hydrophilic component. PEG is widely considered a non-immunogenic, non-toxic compound with decades of use in food, cosmetic, and pharmaceutical products. However, recent studies have begun to indicate that there may be an immunogenic response to PEG-containing materials, especially with regard to intravenous products (see: Garay, R. et al., Expert Opin. Drug Delivery, 2012, 1319-1323; Yang, Q. et al., Anal. Chem. 2016, 88(23), 11804-11812; Wenande, E. et al., Clin. Exp. Allergy, 2016, 46(7), 907-922; Webster, R. Drug Metab. Dispos, 2007, 35(1), 9-16).Pharmaceuticals containing PEGs can also produce infusion-related reactions (see: Browne, EK et al. J. Pediatr Oncolo. Nurs. 2018, 35(2), 103). Furthermore, the manufacture of pharmaceutically acceptable, high-purity PEG derivatives involves the extremely hazardous polymerization of ethylene oxide, and even trace impurities in the product can have significant effects on its applications (see: Vojkovsky, T. et al. Polymer, 2016, 105, 72-78; Sill, K. et al. Biomacromolecules 2017, 18(6), 1874-1884). This can make the use of PEG-containing pharmaceuticals expensive and thus cost-prohibitive for certain applications. Other polymers commonly used for drug delivery applications are based on acrylate or other vinyl polymer chemistries. Such polymers are prepared by the anionic or radical polymerization of vinyl monomers. Often, these monomers, such as butyl acrylate, are strong sensitizing agents. Furthermore, while these polymers are biocompatible, they do not degrade in vivo because the polymer backbone chain is composed exclusively of carbon-carbon bonds. Brief description of the disclosure This disclosure relates to multiblock copolymers comprising a hydrophilic poly(sarcosine) block and a hydrophobic poly(amino acid) block comprising a mixture of D- and L-amino acids. Multiblock copolymers can be synthesized by polymerizing the corresponding amino acid N-carboxyanhydrides. As described herein, multiblock copolymers are useful for encapsulating hydrophobic molecules, thereby increasing the molecule's solubility in aqueous solutions. Compositions described herein include pharmaceutical products comprising a multiblock copolymer and a hydrophobic drug. Such compositions increase the solubility of the hydrophobic drug in diluents commonly used for parenteral administration. Methods for preparing a composition or unit-dose form described herein are also provided. Brief description of the figures Figure 1. Rat pharmacokinetic profile of TYN-21 versus Abraxane at paclitaxel doses MA / t / ZUZZ / UO4ZÓ Ί equivalent of 5.0 mg / kg. Detailed description of certain disclosure methods 1. General Description As described herein, this disclosure pertains to multiblock poly(amino acid) copolymers. The first block is a hydrophilic poly(sarcosine) block, and the second is a hydrophobic poly(amino acid) block comprising a mixture of D- and L-amino acids. Such biopolymers can spontaneously self-assemble into micellar structures in aqueous solutions, with the hydrophilic poly(sarcosine) block forming the crown and the hydrophobic poly(amino acid) block forming the core of the micelle. If a hydrophobic molecule (e.g., an API, compound, drug, or pharmaceutically active agent) is present during this assembly, it can be sequestered in the hydrophobic portion of the micelle. This will have the effect of increasing the solubility of the hydrophobic molecule in aqueous solutions.The amide backbone of a poly(sarcosine) block can adopt both cis and trans configurations, whereas a poly(amino acid) block comprising a mixture of both D- and L-amino acids will disrupt the formation of secondary and tertiary structures. Without wishing to commit to a particular theory, it is believed that these two properties, taken together, increase the rotational degrees of freedom, allowing the multiblock poly(amino acid) copolymer to assume many conformations, which promotes the lowest possible energy state for an associated hydrophobic molecule. It will be appreciated that if the hydrophobic molecule is a hydrophobic drug, the compositions of this disclosure will be useful for parenteral administration using common aqueous diluents (e.g., saline or D5W) without the need for additional solubilizing agents, such as Cremophor® EL (polyoxyethylated castor oil).A technician in the field will recognize the advantage of eliminating the need for Cremophor EL, which is known to cause several infusion-related side effects, including bronchospasm, hypotension, peripheral neuropathy, and anaphylactic reactions. These side effects necessitate premedication with H1 and H2 antagonists and prolonged infusion times to reduce hypersensitivity reactions for paclitaxel formulations based on Cremophor EL (see: Authier, N. et al., Neurotox. Res. 2001, 3, 301-306; Gelderblom, H. et al., Eur. J. Cancer 2001, 37, 1590-1598; Brat, D. et al., Pharmacology Exp. Ther. 1992, 261, 803-810; Windebank, AJ et al., J. Pharmacology Exp. Ther. 1994, 268, 1051-1056; Van Zuylen, L. et al., Investigational New Drugs, 2001, 19, 125-141). Cremophor EL is also incompatible with intravenous tubing. standards since it extracts the plasticizer DEHP (di(2-ethylhexyl) phthalate) from vinyl chloride (PVC) materials.Additionally, drugs formulated with Cremophor EL (e.g., paclitaxel) can be trapped in Cremophor micelles, resulting in nonlinear pharmacokinetics (see: Sparreboom, A. et al., Cancer Res, 1999, 59, 1454-1457). In some embodiments, the poly(amino acid) copolymers of this disclosure can be prepared by polymerizing the corresponding amino acid N-carboxyanhydrides (NCAs). The multiblock copolymers of this disclosure can be prepared by sequentially polymerizing sarcosine NCAs followed by a mixture of D- and L-amino acid NCAs. In some embodiments, the polymerization is carried out in a single solvent and the final copolymer is isolated via precipitation with a single antisolvent. The solvents and reagents are used “as received,” without additional steps taken to purify them or to exclude air and / or moisture (e.g., Schlenk techniques), as is commonly employed in NCA polymerizations (see: Aliferis, T. et al. Biomacromolecules 2004, 5(5), 1653; Deming, TJ et al. Nature 1997, 390(6658), 386; Kricheldorf, HR α-Amino acid-N-carboxy-anhydrides and related heterocycles: syntheses, properties, peptide synthesis, polymerization, Berlin, Springer-Verlag, 2011). It will be appreciated that this will minimize the cost associated with preparing a poly(amino acid) copolymer, especially on a commercial scale under Good Manufacturing Practice (GMP) guidance, since it will be necessary to obtain a minimum number of solvents and quantify them during release tests. 2. Definitions: The following are definitions of various terms used to describe this disclosure and are further illustrated in the categories, subcategories, and species disclosed herein. These definitions apply to the terms as used throughout this specification unless otherwise indicated in specific instances, either individually or as part of a larger group. For the purposes of this disclosure, chemical elements are identified according to the periodic table of the elements, CRC Handbook of Chemistry and Physics, 100th ed. Additionally, general principles of organic chemistry are described in: Sorrell, T. Organic Chemistry, 2nd ed., Sausalito, University Science Books, 2005; and Smith, M. B. March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th ed., New York, J. John Wiley & Sons, 2001, the contents of which are incorporated herein by reference. The term “approximately” when referring to an average value, such as quantity, time duration, and the like, refers to variations of ±20% or in some cases ±10%, or in some cases ±5%, or in some cases ±2%, or in some cases ±1%, or in some cases ±0.1% of the specified value, as such variations are appropriate for making these disclosures. The terms “TFS-1”, “poly(sarcosine)175-b / oqL / e-pol¡(cy-leucine35-co-tyrosine25)”, “PSari75-P(dLeu35 / Tyr25)”, “poly[Sari75]-b / oque-po / / -[D-Leu35-co-L-Tyr25]”, and a copolymer having the following structure are understood to mean: They all represent the same compound and can be used interchangeably. The terms “TFS-2”, “pol¡(sarcos¡na)i75-¿> / o<7ue-poli(cMeucina30-co-t¡ros¡na20)”, “PSari75-P(dLeu3o / Tyr2o)”, “poli[Sari75]-b / oque-po / / -[D-Leu3o-co-L-Tyr2o]”, and a copolymer having the following structure are understood to mean: They all represent the same compound and can be used interchangeably. The terms “TFS-3”, “pol(sarcosine)235-Woque-poly(c-phenylalanine-co-tyrosinase)”, “PSar235-P(dPheio / Tyr3o)”, “poly[Sar235]-Woque-poly-[D-Pheio-co-L-Tyr3o]”, and a copolymer having the following structure are understood to mean: They all represent the same compound and can be used interchangeably. As used herein, the term "block copolymer" refers to a polymer comprising two or more poly(amino acid) units. As described herein, one or more of the amino acid units may be "mixed blocks," meaning that these blocks may contain a mixture of amino acid monomers, thereby creating the block copolymers of this disclosure. A person skilled in the art will recognize that a repeating monomer unit is defined by parentheses enclosing the repeating monomer unit. The number (or letter representing a numerical range) to the lower right of the parentheses represents the number of monomer units present in the polymer chain. In the case where only one monomer constitutes the block (for example, a homopolymer), the block is denoted solely by the parentheses. In the case of a mixed block, multiple monomers comprise a single continuous block.Square brackets will be understood to define a portion of a block. For example, a block may consist of four individual monomers, each defined by its own individual set of parentheses and number of repeating units present. The four sets of parentheses will be enclosed by a set of square brackets, denoting that these four monomers combine in a random, or near-random, order to comprise the mixed block. For clarity, the randomly mixed block [BCADDCBADABCDABC] would be abbreviated as [(A)4(B)4(C)4(D)4]. As used herein, the monomer repeating unit described above is a numerical value representing the average number of monomer units comprising the polymer chain. For example, a polymer represented by (A)io corresponds to a polymer consisting of ten “A” monomer units linked together. A person skilled in the art will recognize that the number 10 in this case represents a distribution of numbers with an average of 10. The spread of this distribution is represented by the polydispersity index (PDI). A PDI of 1.0 represents a polymer in which each chain length is exactly the same (for example, a protein). A PDI of 2.0 represents a polymer in which the chain lengths have a Gaussian distribution. The polymers in this disclosure typically have a PDI of less than 1.20. As used herein, “multiblock copolymer” or “copolymer” refers to a polymer comprising two or more poly(amino acid) blocks. As used herein, the term “poly(amino acid”) or “amino acid block” refers to a covalently linked chain of amino acids, where each monomer is an amino acid unit. Such amino acid units include both naturally occurring and non-naturally occurring amino acids. Such poly(amino acids) include those having suitably protected functional groups. For example, amino acid monomers may have hydroxyl or amino moieties, which are optionally protected by a hydroxyl protecting group or an amino protecting group, as appropriate. As used herein, an amino acid block comprises one or more monomers or a set of two or more monomers. In certain embodiments, an amino acid block comprises one or more monomers such that the overall block is either hydrophilic or hydrophobic.Still in other forms, the amino acid blocks of this disclosure include random amino acid blocks, which include blocks comprising a mixture of amino acid residues. Exemplary poly(amino acids) include poly(D-leucine-co-tyrosine), and poly(D-phenylalanine-co-tyrosine). As used herein, the term “mixed D,L-poly(amino acid) block” refers to a poly(amino acid) block in which the poly(amino acid) consists of a mixture of amino acids in both D and L configurations. In certain embodiments, the mixed D,L-poly(amino acid) block is hydrophobic. In other embodiments, the mixed D,L-poly(amino acid) block consists of a mixture of hydrophobic D-configured amino acids and hydrophilic amino acid side chain groups, such that the overall poly(amino acid) block comprising them is hydrophobic. As used herein, the phrase “natural amino acid” refers to any amino acid that occurs in proteins and those that occur in nature. Such natural amino acids include the nonpolar, or hydrophobic, amino acids glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline. Cysteine ​​is sometimes classified as nonpolar or hydrophobic and sometimes as polar. Natural amino acids also include polar, or hydrophilic, amino acids such as tyrosine, serine, threonine, aspartic acid (also known as aspartate when charged), glutamic acid (also known as glutamate when charged), asparagine, and glutamine. Certain polar, or hydrophilic, amino acids have charged side chains. Such charged amino acids include lysine, arginine, and histidine.A person skilled in the field would recognize that protecting a polar or hydrophilic amino acid side chain can make that amino acid nonpolar. For example, a suitably protected hydroxyl group on tyrosine can make that tyrosine nonpolar and hydrophobic by virtue of protecting the hydroxyl group. For clarity, sarcosine is a naturally occurring amino acid. As used herein, the phrase “natural amino acid side chain group” refers to the side chain group of any natural amino acid, as defined herein. For clarity, the -CHE side chain group would represent the amino acid alanine, a naturally occurring amino acid side chain group. As used herein, the phrase “non-natural amino acid” refers to any amino acid not included in the list of those amino acids that occur naturally in proteins, as described above. Non-natural amino acids also include homoserine, ornithine, and tyrosine. Exemplary non-natural amino acids include β-trityl-asparagine, β-benzylaspartate, S-benzyl-cysteine, cyclohexylglycine, γ-benzyl-glutamate, γ-tert-butyl-glutamate, ε-trifluoroacetyllysine, ε-Boc-lysine, ε-benzyl-lysine, β-benzyl-serine, and O-acetyl-tyrosine. Other non-natural amino acids include modified amino acids, which include those that are N-alkylated, cyclized, phosphorylated, acetylated, amidated, azidylated, tagged, and the like. As used herein, the phrase “non-natural amino acid side chain group” refers to the side chain group of any non-natural amino acid, as defined herein. For clarity, the side chain group -(CHjsCOaCHzCsHs) would represent γ-benzyl-glutamate, a non-natural amino acid side chain group. As used herein, the term “amino acid” is understood to be a generic term encompassing both naturally occurring and non-naturally occurring amino acids. The term “D-amino acid” is understood to refer to a naturally occurring or non-naturally occurring amino acid with the D configuration. The term “lamino acid” is understood to refer to a naturally occurring or non-naturally occurring amino acid with the L configuration. As used herein, the term “tacticity” refers to the stereochemistry of the poly(amino acid) building block. A poly(amino acid) building block consisting of a single stereoisomer (e.g., all L-isomers) is referred to as “sotactic.” A poly(amino acid) consisting of a random incorporation of D- and L-amino acid monomers is referred to as an “atactic” polymer. A poly(amino acid) with alternating stereochemistry (e.g., ...DLDLDL...) is referred to as a “syndiotactic” polymer. Polymer tacticity is described in more detail in: Odian, G. Principles of Polymerization, 4th ed., New York, John Wiley & Sons, 1991, the full contents of which are incorporated herein by reference. As used herein, the phrase “live polymer chain end” refers to the term resulting from a polymerization reaction that retains the ability to react further with additional monomer or with a polymerization terminator. As used herein, the term “termination” refers to attaching a terminal group to a polymer chain end by reacting a living polymer with an appropriate compound. Alternatively, the term “termination” may refer to attaching a terminal group to an amine or hydroxyl end, or a derivative thereof, of the polymer chain. As used herein, the term “polymerization terminator” is used interchangeably with the term “polymerization terminating agent” and refers to a compound that reacts with a living polymer chain end to give a polymer with a terminal group. Alternatively, the term “polymerization terminator” may refer to a compound that reacts with an amine or hydroxyl end, or derivative thereof, of the polymer chain to give a polymer with a terminal group. As used herein, the term “polymerization initiator” refers to a compound that reacts with, or whose anion or free base form reacts with, the desired monomer in a manner that results in polymerization of that monomer. In certain embodiments, the polymerization initiator is an amine. The term “aliphatic” or “aliphatic group,” as used herein, denotes a hydrocarbon part that may be linear (i.e., unbranched), branched, or cyclic (including fused, bridging, and polycyclic spiro-fused) and may be fully saturated or contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1–20 carbon atoms. In some embodiments, aliphatic groups contain 1–10 carbon atoms. In other embodiments, aliphatic groups contain 1–8 carbon atoms. Still in other embodiments, aliphatic groups contain 1–6 carbon atoms, and in still others, aliphatic groups contain 1–4 carbon atoms. The number of carbon atoms present in aliphatic groups may also be defined prior to the declaration of such an aliphatic group.For example, the term aliphatic(C1-C6) refers to an aliphatic group as defined herein comprising 1 to 6 carbon atoms. It is specifically intended that disclosure include each and every individual subcombination of the members of such ranges. In particular, the term aliphatic(C1-C6) is intended to include C1 aliphatic (e.g., methyl), C2 aliphatic (e.g., ethyl, ethylene, or ethylyle), C3 aliphatic, C4 aliphatic, C5 aliphatic, and C6 aliphatic. Aliphatic groups include, but are not limited to, linear or branched alkyl, alkenyl, and alkynyl groups, and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl. The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon. This includes any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a replaceable nitrogen of a heterocyclic ring including =N- as in 3,4-dihydro-2 / - / -pyrrolyl, -NH- as in pyrrolidinyl, or =N(Rf)- as in N-substituted pyrrolidinyl. The term “unsaturated”, as used herein, means that a part has one or more units of unsaturation. The term “aryl,” used alone or as part of a larger part as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, where at least one ring in the system is aromatic and where each ring in the system contains three to seven ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” As described herein, disclosures may contain 'Optionally Substituted' parts. In general, the term 'substituted', whether preceded by the term MA / Ί 'Optionally' or not means that one or more hydrogens of the designated portion are replaced with a suitable substituent. In some embodiments, an 'optionally substituted' group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be the same or different at each position. In some embodiments, an 'optionally substituted' group refers to a group having 0-5 substituents selected independently from a specified group. In some embodiments, an 'optionally substituted' group refers to a group having 0-3 substituents selected independently from a specified group. The combinations of substituents provided for in this disclosure are preferably those that result in the formation of stable or chemically feasible compounds.The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to permit their production, detection and, in certain modalities, their recovery, purification and use for one or more of the purposes disclosed herein. The substituents on a replaceable carbon atom of an “optionally substituted” group are independently halogen; -(CH2)o-4R°; -(CH2)o^OR°; -O-(CH2)o-4C(O)OR°; -(CH2)o-4CH(OR°)2; (CH2)o-4SR°; -(CH2)o-4Ph, which may be substituted with R°; -(CH2)o-4O(CH2)o-iPh, which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -NO2; -CN; -N3; ​​-(CH2)o-4N(R°)2; (CH2)o-4N(R°)C(O)R°; -N(R°)C(S)R°; -(CH2)o-4N(R0)C(O)NR02; -N(Ro)C(S)NR°2; -(CH2)o-4N(R°)C(0)OR°; N(R°)N(R°)C(O)R°; -N(Ro)N(R°)C(O)NRo2; -N(Ro)N(R°)C(O)OR°; -(CH2)o-4C(0)R°; -C(S)R°; -(CH2)o4C(O)ORo; -(CH2)o-4C(0)SR°; -(CH2)o-4C(0)OS¡R°3; -(CH2)o-40C(0)R°; -OC(0)(CH2)o-4SR-, SC(S)SR°; (CH2)o-4SC(0)R°; -(CH2)o-4C(0)NR°2; -C(S)NRo2; -C(S)SR°; -SC(S)SR°, -(CH2)o-40C(0)NR°2; C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -C(NOR°)R°; -(CH2)o-4SSR°; -(CH2)o-4S(0)2R°; -(CH2)o4S(O)2OR°; -(CH2)o-40S(0)2R°; -S(O)2NRo2; -(CH2)o-4S(0)R°; -N(Ro)S(O)2NRo2; -N(Ro)S(O)2R°; N(OR°)R°; -C(NH)NR°2; -P(O)2Ro; -P(O)Ro2;-OP(O)Ro2; -OP(O)(ORo)2; SiRo3; -(linear or branched Ci-4 alkylene)ON(R°)2; or -(linear or branched Ci-4 alkylene)C(O)ON(R°)2, wherein each R° can be substituted as defined below and is independently hydrogen, aliphatic (Ci-6), CH2Ph, O(CH2)o-iPh, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur or, regardless of the above definition, two independent occurrences of R°, taken together with intermediate atoms, form a 3-12 membered mono- or bicyclic, aryl, partially unsaturated ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which can be substituted as defined above. Monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intermediate atoms) are independently halogen, -(CH2)o-2R·, -(haloR*), -(CH2)o2OH, -(CH2)o-2OR·, -(CH2)o-2CH(OR· / -(haloR·), -CN, -N3, -(CH2)o-2C(O)R·, -(CH2)o-2C(O)OH, -(CH2)o2C(O)OR·, -(CH2)o2SR·, -(CH2)o2SH, -(CH2)o-2NH2, -(CH2)o-2NHR·, -(CH2)o-2NR*2, -NO2, -SiR*3, -OS¡R*3, C(O)SR* -(linear or branched alkylene of Ci-4)C(O)OR·, or -SSR* wherein each R* is unsubstituted or where it is preceded by “halo” is substituted with only one or more halogens, and is independently selected from aliphatic (Ci-4), -CH2Ph, -O(CH2)o-iPh, or a saturated, partially unsaturated, or aryl 5-6 membered ring having O-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such divalent substituents on a saturated carbon atom of R° include =O and =S. Divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: =0, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, -O(C(R*2))2-3O-, or -S(C(R*2))2-3S-, wherein each independent occurrence of R* is selected from hydrogen, aliphatic(Ci-6) which may be substituted as defined above, or a saturated, partially unsaturated or unsubstituted 5-6 membered ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Divalent substituents attached to vicinal replaceable carbons of an “optionally substituted” group include: -O(CR*2)2-3O- wherein each independent occurrence of R* is selected from hydrogen, aliphatic(Ci-6) which may be substituted as defined above, or a saturated, partially unsaturated or unsubstituted 5-6 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.A tetravalent substituent that attaches to vicinal replaceable methylene carbons of an optionally substituted (OC)3Co^Co(CO)3 group is the dicobalt hexacarbonyl group represented by XX when shown with the bearing methylenes. Suitable substituents on the aliphatic group of R' include halogen, -R·, -(haloR·), -OH, OR·, -O(haloR·), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR·, -NR*2, or -NO2, wherein each R· is unsubstituted or, where it is preceded by “halo”, is substituted with only one or more halogens, and is independently aliphatic (Ci-4), -CH2Ph, -O(CH2)o-iPh, or a saturated, partially unsaturated, or aryl 5-6-membered ring having O-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable substituents on a replaceable nitrogen of an “optionally substituted” group include -Rf, -NRh, -C(O)Rt, -C(O)ORt, -C(O)CH2C(O)Rt, -S(O)2Rt, -S(O)2NRt2, -C(S)NRh, -C(NH)NR+2, or -NΝίΗδίΟΗ1; wherein each Rf is independently aliphatic (Ci-6) hydrogen which may be substituted as defined below, unsubstituted -OPh, or a saturated, partially unsaturated, or unsubstituted 5-6 membered ring having 0-4 independently selected heteroatoms of nitrogen, oxygen, or sulfur, or, regardless of the above definition, two independent occurrences of Rf, taken together with their intermediate atom(s) form a mono-bicyclic ring saturated, partially unsaturated or unsubstituted aryl, having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable substituents on the aliphatic group of Rf are independently halogen, -R·, (haloR·), -OH, -OR·, -O(haloR·), -CN, -C(O)OH, -C(O)OR·, -NH2, -NHR·, -NR*2, or -NO2, wherein each R· is unsubstituted or where it is preceded by “halo” is substituted with only one or more halogens, and is independently aliphatic (Ci-4), -CH2Ph, -O(CH2)o-iPh, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. In some embodiments, an “optionally substituted aliphatic” group refers to an aliphatic group as defined above, which is substituted with 0-5 substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, phenyl, azide, or alkyne, wherein said phenyl is substituted with 0-5 substituents selected from: halogen, -CH3, -CF2H, -CF3, -OCH3, or -OH. For example, an “optionally substituted aliphatic” group may refer to a methyl group that is substituted with a -CeHs group, i.e., a benzyl group (-CHaCeHs). In some embodiments, an “optionally substituted aliphatic” group refers to an aliphatic group as defined above, which is substituted with 0-3 substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, phenyl, azide, or alkyne, wherein said phenyl is substituted with 0-3 substituents selected from: halogen, -CH3, -CF2H, -CF3, -OCH3, or -OH. For example, an “optionally substituted aliphatic” group may refer to a methyl group that is substituted with a CH2C6H5 group, i.e., a benzyl group. Protected hydroxyl groups are well known in the art and include those described in detail in Wuts, PGM Protecting Groups in Organic Synthesis, 5th ed., New York, John Wiley & Sons, 2014, which is incorporated herein by reference. Examples of suitably protected hydroxyl groups also include, but are not limited to, esters, carbonates, sulfonates, allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of suitable esters include formates, acetates, propionates, pentanoates, crotonates, and benzoates. Specific examples of suitable esters include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetate), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate.Examples of carbonates include 9-fluorenylmethyl carbonate, ethyl carbonate, 2,2,2-trichloroethyl carbonate, 2-(trimethylsilyl)ethyl carbonate, 2-(phenylsulfonyl)ethyl carbonate, vinyl carbonate, allyl carbonate, and p-nitrobenzyl carbonate. Examples of silyl ethers include trimethylsilyl ethers, triethylsilyl ethers, tert-butyldimethylsilyl ethers, tert-butyldiphenylsilyl ethers, triisopropylsilyl ethers, and other trialkylsilyl esters. Examples of alkyl ethers include methyl ether, benzyl ether, p-methoxybenzyl ether, 3,4-dimethoxybenzyl ether, trityl ether, tert-butyl ether, and allyl ether, or derivatives thereof. Alkoxyalkyl ethers include acetals such as methoxymethyl ether, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylethyl)ethoxymethyl, and tetrahydropyran-2-yl. Examples of arylalkyl ethers include benzyl ethers, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, phalobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl. Protected amines are well known in the art and include those described in detail in Wuts (2014). Mono-protected amines also include, but are not limited to, aralkylamines, carbamates, allyl amines, amides, and the like. Examples of mono-protected amino moieties include tert-butyloxycarbonylamino (-NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonyl, allyloxycarbonyl (-NHAIIoc), benzylxocarbonylamino (-NHCBZ), allylamino, benzylamino (-NHBn), fluorenylmethylcarbonyl (-NHFmoc), formamide, acetamide, chloroacetamide, dichloroacetamide, trichloroacetamide, phenylacetamide, trifluoroacetamide, benzamide, tert-butyldiphenylsilyl, and the like. Di-protected amines include amines that MA / Ί are substituted with two substituents independently selected from those described above as mono-protected amines, and also include cyclic imides, such as phthalimide, maleimide, succinimide, and the like. Di-protected amines also include pyrroles and the like, 2,2,5,5-tetramethyl[1,25]azadisylolidine and the like, and azide. Protected aldehydes are well known in the art and include those described in detail in Wuts (2014). Protected aldehydes also include, but are not limited to, acyclic acetals, cyclic acetals, hydrazones, imines, and the like. Examples of such groups include dimethyl acetal, diethyl acetal, diisopropyl acetal, dibenzyl acetal, bis(2-nitrobenzyl) acetal, 1,3-dioxanes, 1,3-dioxolanes, semicarbazones, and derivatives thereof. Protected carboxylic acids are well known in the art and include those described in detail in Wuts (2014). Protected carboxylic acids also include, but are not limited to, optionally substituted aliphatic (CI-6) esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, and the like. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl esters, where each group is optionally substituted. Additional protected carboxylic acids include oxazolines and ortho esters. Protected thiols are well known in the art and include those described in detail in Wuts (2014). Protected thiols also include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates, and the like. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioester, to name a few. Unless otherwise stated, the structures represented herein are intended to include all isomeric forms (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, individual stereochemical isomers, as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the compounds herein, are within the scope of disclosure. Unless otherwise stated, all tautomeric forms of the compounds in this disclosure are within the scope of disclosure. Additionally, unless otherwise stated, the structures shown herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms.For example, compounds having the present structures except for the replacement of hydrogen with deuterium or tritium, or the replacement of a carbon atom with an enriched 13C- or 14C-atom, are within the scope of this disclosure. Such compounds are useful, for example, in neutron scattering experiments, as analytical tools, or as probes in biological assays. As used herein, the term “detectable part” is used interchangeably with the term “label” and refers to any part capable of being detected (e.g., primary labels and secondary labels). A “detectable part” or “label” is the radical of a detectable compound. “Primary” labels include parts that contain radioisotopes (e.g., parts that MA / Ί contain 32P, 33P, 35S, or 14C), mass labels, and fluorescent labels, and are signal-generating reporter groups which can be detected without additional modifications. “Secondary” tags include components, such as biotin or protein antigens, that require the presence of a second compound to produce a detectable signal. For example, in the case of a biotin tag, the second compound might include streptavidin-enzyme conjugates. In the case of an antigen tag, the second compound might include an antibody-enzyme conjugate. Additionally, certain fluorescent groups can act as secondary tags by transferring energy to another compound or group in a non-radioactive fluorescent resonance energy transfer (FRET) process, causing the second compound or group to then generate the detectable signal. The terms “fluorescent label”, “fluorescent group”, “fluorescent compound”, “fluorescent dye” and “fluorophore”, as used herein, refer to compounds or parts that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength. Examples of fluorescent compounds include, but are not limited to: Dyes (Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 633, Alexa Fluor® 660 and Alexa Fluor® 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530 / 550, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665), Carboxyrodamine 6G, CarboxyX-rhodamine (ROX), Cascade Blue, Cascade Yellow, Coumarin 343, cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), Dansilo, Dapoxilo, Dialkylaminocoumarin, 4',5'-Dichloro-2',7'-dimethoxy-fluorescein, DM-NERF, Eosin, Erythrosine, Fluorescein, FAM, Hydroxycoumarin, IRD dyes (IRD40, IRD 700, IRD 800), JOE, Lisamine rhodamine B, Marina Blue, Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B, Rhodamine 6G, Rhodamine green, Rhodamine red, Rhodol green, 2',4',5',7'-Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine (TMR), Carboxytetramethylrhodamine (TAMRA), Texas red, Texas-X red. The term “substrate,” as used herein, refers to any material or macromolecular complex to which a multiblock copolymer can bond. Examples of commonly used substrates include, but are not limited to, glass surfaces, silica surfaces, plastic surfaces, metal surfaces, surfaces containing metallic or chemical coatings, membranes (e.g., nylon, polysulfone, silica), microbeads (e.g., latex, polystyrene, or other polymer), porous polymer matrices (e.g., polyacrylamide gel, polysaccharide, polymethacrylate), and macromolecular complexes (e.g., protein, polysaccharide). Unless otherwise stated, radioisotope-containing parts are optionally substituted hydrocarbon groups containing at least one radioisotope. Unless otherwise stated, radioisotope-containing parts contain 1–40 carbon atoms and one radioisotope. In certain embodiments, radioisotope-containing parts contain 1–20 carbon atoms and one radioisotope. The term “isotopic enrichment” or “isotopically enriched” refers to the abundance The relative isotope of an isotope being altered, thus producing a form of the element that has been enriched in a particular isotope and suppressed in its other isotopic forms. For example, a C14 compound is said to have been isotopically enriched. The term “as received” when referring to the use of a solvent, reagent, resin, or other component used in a chemical reaction or isolation refers to its use in the state provided by the manufacturer without any additional isolation, and / or purification. As used herein, the term “hydrophobic molecule” refers to a compound, drug, therapeutic agent, or active pharmaceutical ingredient, and its pharmaceutically acceptable salts. As used herein, the terms “drug”, “therapeutic agent”, “pharmaceutical”, “medicine” and derivatives thereof, as used interchangeably, refer to a substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease. As used herein, the terms “drug-loaded” and “encapsulated,” and derivatives thereof, are used interchangeably. For the purposes of this disclosure, a “drug-loaded” micelle refers to a micelle that has a drug, or therapeutic agent, located within the micelle core. In some cases, the drug, or therapeutic agent, is located at the interface between the core and the hydrophilic crown. This is also referred to as a drug, or therapeutic agent, that is “encapsulated” within the micelle. As used herein, “weight load” refers to the proportion of a drug to the total pharmaceutical formulation, which may include, but is not limited to, drugs, excipients, and copolymers. Weight load is expressed as a weight percentage (% w / w), e.g., 20 mg of a drug in a total formulation that also comprises 90 mg of a cryoprotectant and 90 mg of a copolymer would be expressed as 10% weight load (20 / (20+90+90)=10%). As used herein, “feed ratio” refers to the proportion of drug combined with a copolymer during the manufacture of a pharmaceutical product. The feed ratio is expressed as a weight percentage (% w / w), for example; 100 mg of a drug combined with 500 mg of a copolymer (independent of other components) would be expressed as a feed ratio of 20% (100 / 500=20%). As used herein, “high shear mixing” or “high shear blending” refers to dispersing a combination of components in a continuous phase, which would normally be immiscible, via emulsification, sonication, or microfluidization. As used herein, “unit dosage form” or “unit dosage form” refers to a physically discrete unit of a formulation appropriate for the subject being treated. However, it is understood that the total daily use of the compositions in this disclosure will be determined by the treating physician within the scope of good medical judgment. The specific effective dose level for any particular subject or organism will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific active agent employed; the specific composition employed; the subject’s age, body weight, general health, sex, and diet; the time of administration and the rate of excretion of the specific active agent employed; and the duration of treatment, drugs, and / or therapies. MA / 1 additional used in combination or coinciding with specific compound(s) employed and similar factors well known in medical techniques. As used herein, a “pharmaceutical product” means a therapeutic agent and one or more “excipients” selected from, but not limited to, tonicity agents, cryoprotectants, multiblock copolymers, stabilizing agents, anti-adherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, adsorbents, sweeteners, and vehicles. As those skilled in the art will appreciate, the quantities of each excipient will depend on the therapeutic agent, the route of administration, the desired biological endpoint, and the target cell or tissue. As used herein, a “cryoprotectant” or “cryoprotective agent” refers to compounds that either prevent freezing or prevent damage or alteration to other compounds related to freezing. This includes, but is not limited to: sugars, monosaccharides, disaccharides, polyalcohols, amino acids, glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran, and dextrose. As used herein, a “therapeutically effective amount” means an amount of a substance (e.g., a therapeutic agent, composition, and / or formulation) that elicits a desired biological response. In some modalities, a therapeutically effective amount of a substance is an amount that is sufficient, when administered as part of a dosage regimen to a subject suffering from or susceptible to a disease, disorder, and / or condition, to treat, diagnose, slow the progression of, and / or delay the onset of the disease, disorder, and / or condition. As will be appreciated by those of ordinary technique in this matter, the effective amount of a substance may vary depending on factors such as the desired biological endpoint, the substance being delivered, the target cell or tissue, etc.For example, the effective amount of a compound in a formulation for treating a disease, disorder, and / or condition is the amount that relieves, improves, mitigates, inhibits, slows the progression of, or delays the onset of, reduces the severity of, and / or reduces the incidence of one or more symptoms or features of the disease, disorder, and / or condition. In some modalities, a “therapeutically effective amount” is at least a minimum amount of a compound, or composition containing a compound, that is sufficient to treat one or more symptoms of a disease or disorder associated with proliferative diseases, such as cancer. The term “subject”, as used herein, means a mammal and includes human subjects and animals, such as domestic animals (e.g., horses, dogs, cats, etc.). The terms “treat” or “treating,” as used herein, refer to partially or completely relieving, inhibiting, delaying the onset of, slowing the progression of, improving, and / or mitigating a disease or disorder, or one or more symptoms of the disease or disorder. As used herein, the terms “treatment,” “treating,” and “treating” refer to partially or completely relieving, inhibiting, delaying the onset of, slowing the progression of, improving, and / or mitigating a disease or disorder, or one or more symptoms of the disease or disorder, as described herein. In some modalities, treatment may be administered after one or more symptoms have developed. In some modalities, the term “treating” includes preventing, slowing, or stopping the progression of a disease or disorder. In other modalities, treatment may be administered in the absence of symptoms.For example, treatment can be administered to a susceptible individual before the onset of symptoms (e.g., due to a history of symptoms and / or due to genetic or other susceptibility factors). Treatment can also be continued after symptoms resolve, for example, to delay their recurrence. Thus, in some modalities, the term “treating” includes preventing relapse or the recurrence of a disease or disorder. The term “parenteral” or “parenterally,” as used herein, includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered by the intraperitoneal or intravenous route. The sterile injectable forms of the compositions in this disclosure may be aqueous or oily suspensions. These suspensions may be formulated according to techniques known in the field using dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a parenterally acceptable nontoxic diluent or solvent, for example, a solution in 1,3-butanediol. Acceptable vehicles and solvents that may be used include water, Ringer’s solution, and isotonic sodium chloride solution.In addition, sterile fixed oils are conventionally used as a solvent or suspension medium. The term “TYN-21” is understood to refer to a formulation of paclitaxel, TFS-2, and trehalose where paclitaxel is approximately 13%±2% of the weight load of the formulation. The term “TYN-38” is understood to refer to a formulation of SN-38, TFS-3, and trehalose, wherein SN-38 is approximately 10%±2% of the weight load of the formulation. 3. Description of the exemplary modalities 3.1 Multiblock copolymers In some respects, this disclosure relates to multiblock copolymers comprising a poly(sarcosine) block and a mixed D,L-poly(amino acid) block. In certain embodiments, the disclosure provides a Formula I multiblock copolymer: r,1h Rz R2χ Ry And where: R1aes H or an optionally substituted aliphatic group; R1bes H or an optionally substituted aliphatic group; R2 is H, an optionally substituted aliphatic or CO-aliphatic(C1-C6) group; each Ryes independently produces a secondary chain of D-amino acid; each Rzes independently has a secondary chain of L-amino acid; x is 125-350; and is 5-35; z is 5-35. In some respects, this disclosure refers to multiblock copolymers, wherein the hydrophilic block comprises an N-methyl glycine polymer. Those skilled in the art will recognize that other N-alkyl glycines could be used to produce a water-soluble block (see: Robinson, JW et al. Macromolecules 2013, 46(3), 580). In some embodiments, this disclosure includes multiblock copolymers, wherein the hydrophilic block is poly(N-methyl glycine), poly(N-ethyl glycine), poly(N{n-propyl}) glycine, poly(N-isopropyl) glycine, or poly(N-allyl) glycine. In some respects, this disclosure also includes mixtures of two or more N-alkyl glycines used to construct the water-soluble block, such as a mixture of N-methyl glycine and N-ethyl glycine. In some aspects, this disclosure relates to Formula I multiblock copolymers comprising a poly(sarcosine) block starting from an amine-containing portion with optionally substituted aliphatic groups represented by R1a and R1b. In some embodiments, R1a is a hydrogen and R1b is an optionally substituted aliphatic group. In some embodiments, R1a is an optionally substituted aliphatic group or hydrogen and R1b is an optionally substituted aliphatic group. In some embodiments, this disclosure describes substitutions in R1a and R1b that may add functionality to the Formula I multiblock copolymer that would not otherwise be present, including, but not limited to, a detectable portion, a fluorescent label, or a substrate. Those skilled in the art will recognize that many substitutions of R1a and R1b are possible.The R1ay R1b ​​substitutions visualized by this disclosure include, but are not limited to, in some embodiments, optionally substituted benzyl groups, optionally substituted hydrocarbons, optionally substituted silyl groups, polymers of poly(amino acids), polymers of poly(ethylene glycol), polymers of poly(N-isopropylacrylamide), polymers of poly(acrylamide), polymers of poly(2-oxazoline), poly(ethyleneimine), polymers of poly(acrylic acid), polymers of poly(methacrylate), polymers of poly(vinyl alcohol), polymers of poly(vinylpyrrolidone), and their corresponding amine salts.In some embodiments, the aliphatic group of R1ase is selected from C1-C6 alkyl, C1-C6 alkene, C1-C6 alkyne or C3-C10 cycloalkyl, wherein the C1-C6 alkyl, C1-C6 alkene, C1-C6 alkyne or C3-C10 cycloalkyl is substituted with 0-5 halogens, hydroxy, cyano, nitro, oxo or phenyl, wherein said phenyl is substituted with 0-3 substituents selected from halogen, -CHa, -CF2H, -CF2, -OCH3 or -OH. In some embodiments, the aliphatic group R1b is selected from C1-C6 alkyl, C1-C6 alkene, C1-C6 alkyne, or C3-C10 cycloalkyl, wherein the C1-C6 alkyl, C1-C6 alkene, C1-C6 alkyne, or C3-C10 cycloalkyl is substituted with 0-5 halogens, hydroxy, cyano, nitro, oxo, or phenyl groups, wherein said phenyl is substituted with 0-3 substituents selected from: halogen, -CH3, -CF2H, -CF2, -OCH3, or -OH. In some embodiments, R1b is selected from a benzyl, methoxybenzyl, neopentyl (i.e., CH2C(CH3)3), or hexyl group. In a preferred embodiment, R1a is H and R1bs is neopentyl.In another preferred embodiment, R1aes H and R1bes benzyl. In another preferred embodiment, R1aes H and R1bes p-methylbenzyl. In another preferred embodiment, R1aes H and R1bes p-methoxybenzyl. In another preferred embodiment, R1aes H and R1bes n-hexyl. MA / t / ZUZZ / U04ZÓ Ί In certain embodiments, this disclosure relates to multiblock copolymers comprising a mixed D,L-poly(amino acid) block comprising amino acids such that the block is generally hydrophobic. As defined above for a composition represented by Formula I, Ry and Rz represent a D- and an L-amino acid, respectively. A person skilled in the art will appreciate that the mixed D,L-poly(amino acid) block may comprise one or more naturally occurring amino acid side chain groups or non-natural amino acid side chain groups that are not generally considered hydrophobic, but that the inclusion of a naturally occurring amino acid side chain group or non-natural amino acid side chain group that is hydrophobic may render the block generally hydrophobic.For example, under certain circumstances, tyrosine would be considered a hydrophilic amino acid due to its phenol functionality, but a poly(amino acid) block of (tyrosine)20-co-(leucine)30 is generally hydrophobic, partly due to the inclusion of a substantial amount of leucine (e.g., an excess of hydrophobic units), an amino acid generally considered hydrophobic in the art. It will also be appreciated that protecting groups on amino acid side chains can convert an amino acid generally considered hydrophilic into one generally considered hydrophobic. For example, glutamic acid is generally considered a hydrophilic amino acid in the art. However, carboxylate protection can make the amino acid side chain hydrophobic, as is the case with γ-benzyl-glutamate. In certain forms, each Ryse is derived from a hydrophilic D-amino acid, and each Rzse is derived from a hydrophobic L-amino acid for a composition represented by Formula I. In certain forms, each Ryse is derived from a hydrophobic D-amino acid, and each Rzse is derived from a hydrophilic L-amino acid for a composition represented by Formula I. In certain forms, each Ryse is derived from a hydrophobic D-amino acid, and each Rzse is derived from a hydrophobic L-amino acid for a composition presented by Formula I. In some embodiments, each Ryes independently the side chain of y-benzyl-Dglutamate, D-leucine, D-tyrosine, D-phenylalanine, D-alanine, D-valine, D-isoleucine, D-norleucine, O-acetylD-tyrosine, O-benzyl-D-tyrosine, or ε-D-lysine. In some embodiments, each Rzes independently the side chain of γ-benzyl-L-glutamate, L-leucine, L-tyrosine, L-phenylalanine Lalanine, L-valine, L-isoleucine, L-norleucine, O-acetyl-L-tyrosine, O-benzyl-L-tyrosine, or ε-benzyl-L-lysine. In some embodiments, each Ryes independently the side chain of D-leucine, D-phenylalanine, or D-tyrosine. In some embodiments, each Rzes independently the side chain of L-leucine, L-phenylalanine, or L-tyrosine. As described earlier for a composition represented by Formula I, xyy represents the number of residues for a natural or non-natural D- and L-amino acid in a poly(amino acid) block, respectively. A person skilled in the art will recognize that the selection of Ryy and Rzy, and the selection of yyz values, will vary depending on the final role the end multiblock copolymer is to fulfill. It will also be appreciated, for some desired roles, that the length of the sarcosine block, represented by x, is not independent of yy and z. In some respects, this disclosure refers to multiblock copolymers in which one of the core amino acids, either the D- or L-amino acid, is replaced by another amino acid that will break the helical structure normally adopted by an isotactic poly(amino) acid polymer. Those amino acids described in the disclosure include, but are not limited to, N-substituted glycines (e.g., sarcosine), proline, and / or glycine. In some embodiments, this disclosure refers to Formula I multiblock copolymers, wherein R2 is selected from H, an optionally substituted aliphatic group, CO-aliphatic (C1-C6), or COCH3. This disclosure describes substitutions at R2 that may add functionality to the Formula I multiblock copolymer that should not be present, including, but not limited to, a detectable part, a fluorescent tag, or a substrate. In some embodiments, R2 is selected to form an amide linkage. In a preferred embodiment, R2 is an acetyl group. In another preferred embodiment, R2 is isotopically enriched. Those skilled in the art will recognize that isotopically enriched materials can be useful probes in biological assays, such as quantitative whole-body autoradiography (QWBA) assays, which are useful for determining the distribution of a compound in an animal. In certain embodiments, the disclosure provides a Formula I multiblock copolymer, wherein: R1a is an optionally substituted aliphatic group; R1bes H; R2 is H or COCH3; each Ryes independently produces a secondary chain of D-amino acid; each Rzes independently has a secondary chain of L-amino acid; x is 125-350; and it is 5-35; z is 5-35. In certain embodiments, the disclosure provides a Formula I multiblock copolymer, wherein: R1a is an optionally substituted aliphatic group; R1bes H; R2 is H or COCH3; each Ryes is a secondary amino acid chain that corresponds to that of D-leucine; each Rzes is a secondary amino acid chain that corresponds to that of L-tyrosine; x is 125-350; and it is 5-35; z is 5-35. One disclosure modality provides a multiblock copolymer represented by the following structure: ML / Ί MA / Ί TFS-1 Another disclosure modality provides a multiblock copolymer represented by the following structure: TFS-2 One disclosure modality provides a multiblock copolymer represented by the following structure: TFS-1-Ac One disclosure modality provides a multiblock copolymer represented by the following structure: TFS-2-Ac One disclosure modality provides a multiblock copolymer represented by the following structure: TFS-3 One disclosure modality provides a multiblock copolymer represented by the following structure: TFS-3-Ac 3.2 Synthesis of multiblock copolymers In certain embodiments, the disclosure provides methods for preparing multiblock copolymers comprising a poly(sarcosine) block and a mixed D,L-poly(amino acid) block. One embodiment of a general method for preparing such multiblock copolymers is shown in Scheme 1 and comprises the following steps: 1) initiating the polymerization of NCA sarcosine (Formula III) with a suitable amine-containing initiator (Formula II), 2) adding a mixture comprising one or more NCA D-amino acids (Formula IVy), and one or more NCA L-amino acids (Formula IVz) to the live polymerization. Scheme 1 R1b IχΝΗ R1a III Yo In some cases, it may be advantageous to add an NCA to the reaction as a solution rather than a solid. For example, during large-scale manufacturing, solutions are easier to handle than solids. In some embodiments of this disclosure, an NCA of either Formula III, Formula IVy, or Formula IVz is added to the reaction as a solid. In another embodiment, an NCA of either Formula III, Formula IVy, or Formula IVz is added to the reaction as a solution. In certain embodiments, this solvent is the same solvent used to solubilize initiator II. In a preferred embodiment, the solvent is N,N-dimethylformamide. In another preferred embodiment, the solvent is N,N-dimethylacetamide. As described herein, in certain embodiments, the mixed D,L-poly(amino acid) block of Formula I is prepared by polymerizing NCAs derived from natural and non-natural amino acids. In some embodiments, the NCAs of Formula IVy and Formula IVz are selected so that the resulting poly(amino acid) block is generally hydrophobic. As discussed previously, the inclusion of an amino acid generally considered hydrophilic does not necessarily prevent the block from being generally hydrophobic. Accordingly, in certain embodiments, the NCA of Formula IVy is derived from a hydrophilic D-amino acid, and the NCA of Formula IVz is derived from a hydrophobic L-amino acid. In other embodiments, the NCA of Formula IVy is derived from a hydrophobic D-amino acid, and the NCA of Formula IVz is derived from a hydrophilic L-amino acid.In other forms, the NCA of Formula IVy is derived from a hydrophobic D-amino acid, and the NCA of Formula IVz is derived from a hydrophobic L-amino acid. In certain embodiments, the process shown in Scheme 1 is carried out in a single solvent. The solvent must be capable of solubilizing the starting materials, the living polymer chain, and the final copolymer such that all the material remains in solution throughout the entire process. Amide-containing solvents are suitable for this process. In a preferred embodiment, the organic solvent is N,N-dimethylformamide (DMF). In another preferred embodiment, the solvent is N,N-dimethylacetamide (DMAc). In certain embodiments, the Formula II initiator is a primary amine, wherein R1a is a hydrogen atom and R1b is an optionally substituted aliphatic group. In certain embodiments, the Formula II initiator is a secondary amine, wherein R1a is an optionally substituted aliphatic group and R1b is an optionally substituted aliphatic group. A person skilled in the art will recognize that many primary and many secondary amines would be suitable for initiating a polymerization reaction with an NCA.The initiators described in this disclosure include, but are not limited to, optionally substituted benzylamines, optionally substituted hydrocarbon amines, optionally substituted silylamines, poly(amino acid) polymers, poly(ethylene glycol) polymers, poly(N-isopropylacrylamide) polymers, poly(acrylamide) polymers, poly(2-oxazoline) polymers, poly(ethyleneimine) polymers, poly(acrylic acid) polymers, poly(methacrylate) polymers, poly(vinyl alcohol) polymers, poly(vinylpyrrolidone) polymers, and their corresponding amine salts. In a preferred embodiment, the Formula II initiator is selected from benzylamine, p-methylbenzylamine, p-methoxybenzylamine, or n-hexylamine. In a preferred embodiment, the Formula II initiator is neopentylamine represented by the following structure: MA / 1 In some embodiments, disclosure refers to a method for preparing a Formula I compound using reagents, solvents, resins, and other components used in a chemical reaction or isolation as received. In some embodiments, a Formula I compound is prepared without any measures taken to exclude air and / or moisture (e.g., Schlenk techniques). Those technically skilled in this area will appreciate the advantage of NCA polymerization reactions under these conditions, as it will reduce costs and increase the robustness of such processes. This disclosure also relates to the isolation of a Formula I multiblock copolymer from a reaction mixture using a single antisolvent. In some embodiments, the reaction mixture-to-antisolvent ratio is such as to minimize the total amount used. Those skilled in the art will recognize the advantage of using a minimal amount of antisolvent, as it can reduce cost and complexity and increase the scale of preparation. Such reaction mixture-to-antisolvent ratios contemplated by this disclosure include, but are not limited to, 1:0.25, 1:0.5, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:5, and 1:10. This disclosure pertains to the use of a single reaction solvent and a single antisolvent. Those skilled in the art will recognize the advantage of using only two total solvents for the preparation of a Formula I compound, as it will minimize costs, especially on a commercial scale under Good Manufacturing Practice (GMP) guidance, since a minimal quantity of solvents will need to be obtained and quantified during release testing. In certain embodiments, the antisolvent is selected from a list that includes, but is not limited to, a ketone-containing solvent, a hydroxyl-containing solvent, an ester-containing solvent, an ether-containing solvent, a hydrocarbon solvent, an aromatic solvent, and an aqueous solvent. The anti-solvents visualized in the disclosure include, but are not limited to, methyl ethyl ketone, acetone, butanone, ethanol, methanol, isopropanol, butanol, tert-butanol, methyl acetate, butyl acetate, diethyl ether, dioxane, tetrahydrofuran, hexane, heptane, toluene, benzene, water, aqueous buffer solutions. In a preferred embodiment, the antisolvent is ethyl acetate. In another preferred embodiment, the antisolvent is methyl tert-butyl ether. As described earlier, R2 for compounds of Formula I is an optionally substituted aliphatic group. Those technically skilled in the field will recognize that when R2 is H (Formula IV), treatment with a terminating agent would be one method to alter the substitution at R2. Such terminating agents, represented by R2-LG in Scheme 2, include any R2 group capable of reacting with the terminal amine of a compound of Formula IV. Scheme 2 I saw Those technically skilled in the field will recognize that many R2-LG terminating agents are capable of reacting with the terminal amine of a compound represented by Formula V and its corresponding anion. R2-LG terminating agents described in the disclosure include anhydrides, sulfonyl halides, and other acylating agents, and groups containing a leaving group (LG) that is susceptible to nucleophilic displacement. In a preferred embodiment, the terminating agent is acetic anhydride, represented by the following structure: Those skilled in the art will recognize that the treatment of a compound of Formula V with a terminating agent represented by R2-LG can be performed at the conclusion of an NCA polymerization, yielding a compound of Formula V such that the method for preparing a compound of Formula I is carried out as a "one-pot" synthesis. Alternatively, the treatment with R2-LG can be performed after the isolation of a compound of Formula V from a reaction mixture in a "multi-step" process. In some embodiments, a compound of Formula I is prepared in a one-pot process. In other embodiments, a compound of Formula I is prepared in a multi-step process. 3.3 Micelles In certain forms, this disclosure refers to polymeric micelles. It will be appreciated that multiblock poly(amino acid) copolymers comprising a hydrophilic block and a hydrophobic block will spontaneously self-assemble into micelles in aqueous solutions. Someone technically skilled in the field will recognize that a poly(sarcosine) block is hydrophilic. Without wishing to link to a particular theory, it is generally believed that a multiblock copolymer comprising poly(sarcosine) and a poly(amino acid) block will form a micelle with the poly(sarcosine) block forming a hydrophilic crown and the hydrophobic poly(amino acid) block forming the micelle core. The poly(amino acid) block in the disclosure consists of a mixture of D- and L-amino acids. Without wishing to link to a particular theory, it is believed that the incorporation of an atactic poly(amino acid) block disrupts the formation of secondary and tertiary structures normally adopted by isotactic poly(amino acids) such as proteins. This results in the formation of micelles constructed from copolymers containing atactic poly(amino acids) that have different physical properties than those of micelles constructed from copolymers containing equivalent isotactic poly(amino acids). These physical properties include, but are not limited to, critical micelle concentration, solubility, and drug loading efficiency. In certain embodiments, the disclosure refers to Formula I multiblock poly(amino acid) copolymers, which can self-assemble into multimolecular micelles in aqueous solutions when their concentration is above the critical micelle concentration. Such micelles are useful for the encapsulation of hydrophobic molecules, including, but not limited to, drugs, therapeutic agents, diagnostic agents, and probes. 3.4 Drug Load In certain embodiments, the disclosure refers to polymeric micelles, which encapsulate a hydrophobic molecule, thereby increasing the molecule's solubility in aqueous solutions. Without wishing to link to a particular theory, it is believed that when a hydrophobic molecule is present with a Formula I multiblock copolymer in aqueous solution, the molecule will be sequestered in the hydrophobic portion of the multiblock copolymer and will have the effect of increasing the hydrophobic molecule's solubility. When the multiblock copolymer forms a micelle, the hydrophobic molecule will be sequestered in the hydrophobic core of the micelle and thus become soluble in water by the hydrophilic crown of the micelle. In certain embodiments, the hydrophobic molecule is a drug. In some embodiments, the disclosure provides a composition comprising a hydrophobic molecule and a Formula I multiblock copolymer. In some embodiments, the hydrophobic molecule is a drug. In certain embodiments, this disclosure provides drug-loaded micelles in which the drug is selected from a list including, but not limited to, paclitaxel, docetaxel, cabazitaxel, and SN-38, and pharmaceutically acceptable salts thereof. In some embodiments, the disclosure provides a composition comprising TFS-1 multiblock copolymer and a hydrophobic molecule. In a preferred embodiment, the hydrophobic molecule is a drug selected from a list consisting of paclitaxel, docetaxel, cabazitaxel, and SN-38, and pharmaceutically acceptable salts thereof. In some embodiments, the disclosure provides a composition comprising TFS-2 multiblock copolymer and a hydrophobic molecule. In a preferred embodiment, the hydrophobic molecule is a drug selected from a list consisting of paclitaxel, docetaxel, cabazitaxel, and SN-38, and pharmaceutically acceptable salts thereof. In some embodiments, the disclosure provides a composition comprising TFS-3 multiblock copolymer and a hydrophobic molecule. In a preferred embodiment, the hydrophobic molecule is a drug selected from a list consisting of paclitaxel, docetaxel, cabazitaxel, and SN-38, and pharmaceutically acceptable salts thereof. The weight loading of a particular hydrophobic molecule depends on the specific composition of a Formula I multiblock copolymer. Those skilled in the art will recognize that a range of weight loadings for a hydrophobic molecule is possible with this disclosure. It will also be recognized that the weight loading can be adjusted to meet the needs of a particular formulation, such as the solubility of the resulting formulation, stability, and cost reduction. In some embodiments, the hydrophobic molecule is a drug, and the weight loading of that drug ranges from approximately 1% to approximately 25% of the composition. In some embodiments, the disclosure provides compositions comprising a Formula I multiblock copolymer and a drug, wherein the drug is approximately 1% to approximately 5% of the composition. In some embodiments, the disclosure provides compositions comprising a Formula I multiblock copolymer and a drug, wherein the drug is approximately 5% to approximately 10% of the composition. In some embodiments, the disclosure provides compositions comprising a Formula I multiblock copolymer and a drug, wherein the drug is approximately 10% to approximately 15% of the composition. In some embodiments, the disclosure provides compositions comprising a Formula I multiblock copolymer and a drug, wherein the drug is approximately 15% to approximately 20% of the composition. In some embodiments, the disclosure provides compositions comprising a Formula I multiblock copolymer and a drug, wherein the drug is approximately 20% to approximately 25% of the composition. 3.5 Pharmaceutical products The disclosure provides compositions useful for encapsulating hydrophobic drugs. Such compositions may be provided as pharmaceutical products for the treatment of a patient in need thereof. In some embodiments, the disclosure provides pharmaceutical products comprising a Formula I multiblock copolymer and a drug. Such compositions may further comprise an excipient, as defined herein. Certain forms of disclosure may be provided as pharmaceutically acceptable compositions. Such compositions include, but are not limited to, pills, tablets, capsules, aqueous suspensions or solutions, suppositories, creams, sprays, syrups, films, skin patches, dermal patches, vaginal rings, and eye drops. In a preferred embodiment, the pharmaceutically acceptable composition is a lyophilized powder. The compositions described in the disclosure can provide a therapeutically effective amount of a drug suitable for the treatment of a subject in need thereof. In a preferred modality, the subject is a human. The disclosure also provides compositions that can be administered to a patient in need. Routes of administration include, but are not limited to, parenteral, oral, sublingual, buccal, rectal, vaginal, ocular, otic, nasal, inhalation, nebulization, cutaneous, subcutaneous, topical, systemic, or transdermal. In some modalities, the compositions in the disclosure may be formulated as part of an implant or device, or be formulated for slow or prolonged release. In one preferred modality, the route of administration is intravenous. In another preferred modality, the route of administration is via a central venous catheter. In yet another preferred modality, the route of administration is via a peripheral venous catheter. In certain forms of disclosure, the compositions are formulated to be administered orally, for example, in the form of capsules, seals, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil in water or a liquid emulsion of water in oil, or as an elixir or syrup, or as lozenges (using an inert base, such as gelatin and glycerin, or sucrose and acacia), and the like. In solid dosage forms for oral administration (capsules, tablets, pills, coated tablets, powders, granules, and the like), the compositions of the disclosure may be mixed with one or more pharmaceutically acceptable vehicles, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) bulking or extender agents, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) dissolution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate;(8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets, and pills, pharmaceutical compositions may also include buffering agents. Solid compositions of a similar type may also be used as fillings in soft and hard gelatin capsules through the use of excipients such as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. In some embodiments, the pharmaceutical products in this disclosure are formulated as liquid dosage forms for oral administration. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. Liquid dosage forms may contain inert diluents commonly used in the field, such as, for example, water or other solvents, and solubilizing and emulsifying agents such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (for example, cottonseed, peanut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, and fatty acid esters or sorbitan and mixtures thereof.Oral compositions may also include adjuvants such as wetting agents, emulsifiers and suspenders, sweeteners, flavorings, colorings, perfumes, and preservatives. In certain formulations, the compositions in the disclosure are formulated for parenteral administration. For example, the compositions in the disclosure may be formulated for parenteral administration by further including one or more pharmaceutically acceptable sterile aqueous or non-aqueous isotonic solutions, dispersions, suspensions, or emulsions, or sterile powders, which can be reconstituted into sterile injectable solutions or dispersions just before use. Compositions for parenteral administration may contain antioxidants, buffers, bacteriostatic agents, and / or solutes, which make the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.Examples of aqueous and non-aqueous vehicles suitable for use in the pharmaceutical compositions of the invention include water, Ringer's solution, an isotonic salt solution, ethanol, polyols (such as 1,3-butanediol, glycerol, propylene glycol, polyethylene glycol, and the like) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. In a preferred embodiment, the compositions of the disclosure are intended for parenteral administration and further comprise a vehicle selected from water, 1,3-butanediol, Ringer's solution, or an isotonic sodium chloride solution. The formulations disclosed herein may be administered for slow, controlled, or prolonged release. The term “prolonged release” is widely recognized in pharmaceutical science and is used herein to refer to the controlled release of a compound or active agent from a dosage form into an environment over (throughout or during) a prolonged period of time, for example, one hour or more. A prolonged-release dosage form will release drug at a substantially constant rate over a prolonged period of time, or a substantially constant amount of drug will be released in increments over a prolonged period of time. The term “prolonged release” as used herein includes the terms “controlled release,” “prolonged release,” “sustained release,” “delayed release,” or “slow release” as these terms are used in pharmaceutical science.In some forms, the extended-release dosage is administered in the form of a patch or a pump. 3.6 Process for improving the solubility of hydrophobic molecules In certain embodiments, this disclosure provides methods for increasing the solubility of hydrophobic molecules in aqueous solution. As described above, the multiblock copolymers of the disclosure can spontaneously self-assemble into micellar structures in aqueous solutions, with the hydrophilic poly(sarcosine) block forming the crown and the hydrophobic poly(amino acid) block forming the core of the micelle. If the hydrophobic molecule is present during this assembly, it can be sequestered (i.e., encapsulated) in the hydrophobic portion of the micelle. This will have the effect of increasing the solubility of the hydrophobic molecule in aqueous solutions. In one aspect, the disclosure relates to a method for increasing the solubility of a hydrophobic molecule in an aqueous solution, comprising encapsulating the hydrophobic molecule in a multiblock copolymer according to this disclosure. One embodiment of the disclosure provides a method for preparing a composition comprising a hydrophobic molecule and a cryoprotectant having enhanced solubility properties in aqueous solution. The general method for providing such a composition comprises the steps of preparing a solution of a cryoprotectant and a multiblock copolymer, according to the disclosure, in water; preparing a solution of a hydrophobic molecule in an organic solvent, thereby resulting in an organic solution; and adding said organic solution to said solution of a cryoprotectant and multiblock copolymer while shear-mixing with a homogenizer to produce a homogeneous emulsion.Process the resulting homogeneous emulsion through a microfluidizer. Process the microfluidizer-extruded solution via tangential flow filtration against an aqueous cryoprotectant solution. Perform sterile filtration of the resulting solution (e.g., aseptic filtration), fill vials under sterile conditions, and freeze-dry under sterile conditions. Suitable cryoprotectants include, but are not limited to: sugars, monosaccharides, disaccharides, polyalcohols, amino acids, glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran, and dextrose. In a preferred embodiment, the cryoprotectant is trehalose. 3.8 Preparation methods In certain aspects, the disclosure is directed to methods for preparing pharmaceutical products comprising a hydrophobic molecule and a Formula I copolymer. In some embodiments, the disclosure relates to a method for preparing a sterile, lyophilized pharmaceutical product comprising a hydrophobic molecule and a Formula I copolymer. This pharmaceutical product would be suitable for administration to a patient. In some embodiments, the disclosure relates to a method for preparing a sterile, lyophilized pharmaceutical product comprising a hydrophobic molecule, a Formula I copolymer, and a cryoprotectant. The general method for providing such a pharmaceutical product comprises the steps of preparing a solution of a cryoprotectant and a Formula I copolymer in an aqueous tert-butanol mixture; preparing a solution of the hydrophobic molecule in tert-butanol; adding the hydrophobic molecule solution to the cryoprotectant and Formula I copolymer solution; sterilely filtering the resulting solution (e.g., aseptic filtration); filling vials under sterile conditions; and lyophilizing the solution under sterile conditions.Suitable cryoprotective agents include, but are not limited to: sugars, monosaccharides, disaccharides, polyalcohols, amino acids, mannitol, glycine, polyvinylpyrrolidine, polyethylene glycol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran, and dextrose. In a preferred embodiment, the cryoprotectant is trehalose or glycine. In some forms, the disclosure refers to a method for preparing a unit dosage form comprising: a) dissolving a hydrophobic molecule, or a pharmaceutically acceptable salt thereof, a Formula I copolymer and, optionally, a cryoprotectant in aqueous tert-butanol, thus forming a mixed solution; and MA / t / ZUZZ / U04ZÓ Ί b) optionally freeze-dry the mixed solution. In some forms, the disclosure refers to a method for preparing a unit dosage form comprising: a) Dissolving the hydrophobic molecule, or a pharmaceutically acceptable salt thereof, in tert-butanol, thus forming a solution of the hydrophobic molecule; b) dissolving a copolymer of Formula I and, optionally, a cryoprotectant in an aqueous solution of tert-butanol, thereby forming a copolymer solution; c) mixing the hydrophobic molecule solution and the copolymer solution, thus forming a mixed solution; and d) optionally freeze-dry the mixed solution. In some forms, the disclosure refers to a method for preparing a unit dosage form comprising: a) Dissolving the hydrophobic molecule, or a pharmaceutically acceptable salt thereof, in tert-butanol, thus forming a solution of the hydrophobic molecule; b) dissolving a copolymer of Formula I and, optionally, a cryoprotectant in an aqueous solution of tert-butanol, thereby forming a copolymer solution; c) mix the hydrophobic molecule solution and the copolymer solution, thus forming a mixed solution; d) filter the mixed solution, thus forming a filtered solution; e) optionally freeze-dry the filtered solution. In one aspect, the disclosure relates to a method for preparing a sterile, lyophilized pharmaceutical product comprising a hydrophobic molecule and a Formula I copolymer. This pharmaceutical product would be suitable for administration to a patient. One embodiment of the disclosure provides a method for preparing a sterile, lyophilized pharmaceutical product comprising a hydrophobic molecule, a Formula I copolymer, and a cryoprotectant. The general method for providing such a pharmaceutical product comprises the steps of preparing a solution of a cryoprotectant and a Formula I copolymer in water; preparing a solution of a hydrophobic molecule in an organic solvent; and adding said solution of hydrophobic molecule to said solution of a cryoprotectant and a Formula I copolymer while shear-mixing with a homogenizer to produce a homogeneous emulsion.Process the resulting homogeneous emulsion through a high-shear mixer (e.g., microfluidizer). Process the solution extruded by the high-shear mixer via tangential flow filtration against an aqueous cryoprotectant solution. Perform sterile filtration of the resulting solution (e.g., aseptic filtration), fill vials under sterile conditions, and freeze-dry under sterile conditions. Suitable cryoprotectants include, but are not limited to: sugars, monosaccharides, disaccharides, polyalcohols, amino acids, glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran, and dextrose. In a preferred embodiment, the cryoprotectant is trehalose. In some forms, dissemination is directed at a method for preparing a form of MA / t / ZUZZ / U04ZÓ Ί unit dosage comprising: a) dissolving a hydrophobic molecule, or a pharmaceutically acceptable salt thereof, a Formula I copolymer and, optionally, a cryoprotectant, in an aqueous solution, thus forming a mixed solution; b) processing the mixed solution through a high-shear mixer, thereby forming a high-shear mixed solution; and c) optionally freeze-dry the high shear mixed solution. In some forms, the disclosure refers to a method for preparing a unit dosage form comprising: a) Dissolving the hydrophobic molecule, or a pharmaceutically acceptable salt thereof, in an organic solvent, thus forming a solution of the hydrophobic molecule; b) dissolving a copolymer of Formula I and, optionally, a cryoprotectant, in an aqueous solution, thus forming a copolymer solution; c) mix the hydrophobic molecule solution and the copolymer solution, thus forming a mixed solution; d) process the mixed solution through a high shear mixer, thereby forming a high shear mixer solution; e) filtering the high-shear mixer solution, thus forming a filtered solution; and f) optionally freeze-dry the filtered solution. In some forms, the disclosure refers to a method for preparing a unit dosage form comprising: a) Dissolving the hydrophobic molecule, or a pharmaceutically acceptable salt thereof, in an organic solvent, thus forming a solution of the hydrophobic molecule; b) dissolving a copolymer of Formula I and, optionally, a cryoprotectant, in an aqueous solution, thus forming a copolymer solution; c) mix the hydrophobic molecule solution and the copolymer solution, thus forming a mixed solution; d) process the mixed solution through a high shear mixer, thereby forming a high shear mixer solution; e) process the high shear mixer solution with a diafiltration system, thus forming a diafiltered solution; f) filter the diafiltered solution, thus forming a filtered solution; and g) optionally freeze-dry the filtered solution. 3.7 Specific Examples This disclosure visualizes multiblock copolymers of the following structures: IX ML / IZ / ZυZZZ / υ04ZύΊ XIII XVII 21st Century XXIII ML / IZ / ZυZZZ / υ04ZύΊ XXV MA / Ί XXVI Examples To help you fully understand this disclosure, the following examples are provided. These examples are for illustrative purposes only and should not be interpreted as limiting this disclosure in any way. XXIX In the Examples, where an amino acid or NCA contains the prefix “D”, then the corresponding amino acid or NCA is the D configuration. Where no such prefix is ​​present, the corresponding amino acid or NCA is the L configuration. In the Examples, unless otherwise stated, all multiblock copolymers are understood to begin with a neopentylamino (CH3)3CH2-NH- group, even if it is not explicitly included in the abbreviated description. For example, Sarx-bp-[D-Leuy-co-L-Tyrz] is the abbreviated description of the following compound: MA / t / ZUZZ / U04ZÓ 1 Analytical methods The following analytical methods were used to characterize the compounds in this disclosure. Infrared (IR) spectroscopy – All samples were analyzed using a PerkinElmer Spectrum 100 FTIR spectrometer equipped with a universal ATR sampling accessory (Diamond / ZnSe). When IR was used to monitor a reaction, an aliquot of approximately 100 pL was taken and measured directly. Solid samples were measured without further handling. Nuclear magnetic resonance (NMR) spectroscopy - All samples were analyzed on a 400 MHz spectrometer with the following parameters: 45s pulse, 2 seconds acquisition time, 5 seconds recycle delay, with 16-32 transients. Permeation chromatography (GPC) analysis – Samples were analyzed using a Shimadzu LC-20AD pump connected in series to: 2 x PSS Gram analytical columns, 100 Å, 8 x 300 mm, 10 pm; 1 x PSS Gram analytical column, 1000 Å, 8 x 300 mm, 10 pm; a Wyatt TREOS II light scattering detector; and a Wyatt Optilab T-rEX refractive index detector. A LiBr-supplemented DMF mobile phase (50 mM) was used at a flow rate of 1.0 mL to elute the analytes. The column temperature was maintained at 45 °C. Run times of 45 minutes were typically used. The number-average (Mn) and peak molecular weight (Mp) of GPC were calibrated using polystyrene molecular weight standards. Paclitaxel HPLC Method - Paclitaxel assay and identity were determined by high-performance liquid chromatography with UV detection at 227 nm. The column used was a Phenomenex Gemini® 5 pm C18 (110 Å, 250 x 4.6 mm) at room temperature. The mobile phase consisted of a 60:40 (v / v) mixture of 10 mM sodium phosphate and acetonitrile. Paclitaxel pharmaceutical product samples were prepared by dissolving the material in the mobile phase. Paclitaxel standards were prepared by dissolving the material in acetonitrile. Separation was achieved with a flow rate of 1.0 mU / min for a total run time of 12 minutes. Cabazitaxel HPLC Method - Assay and identity of cabazitaxel were determined by high-performance liquid chromatography with UV detection at 227 nm. The column used was a Phenomenex Gemini® 5 pm C18 (110 Å, 250 x 4.6 mm) at room temperature. The mobile phase consisted of a 60:40 (v / v) mixture of 10 mM sodium phosphate and acetonitrile. Cabazitaxel pharmaceutical product samples were prepared by dissolving the material in the mobile phase. Cabazitaxel standards were prepared by dissolving the material in acetonitrile. Separation was achieved with a flow rate of 1.0 mU / min for a total run time of 8 minutes. HPLC Method for Docetaxel – Docetaxel assay and identity were determined by high-performance liquid chromatography with UV detection at 227 nm. The column used was a Phenomenex Gemini® 5 pm C18 (110 Å, 250 x 4.6 mm) at room temperature. The mobile phase consisted of a 60:40 (v / v) mixture of 10 mM sodium phosphate and acetonitrile. Docetaxel pharmaceutical product samples were prepared by dissolving the material in the mobile phase. Docetaxel standards were prepared by dissolving the material in acetonitrile. Separation was achieved with a flow rate of 1.0 mU / min for a total run time of 8 minutes. HPLC Method for SN-38 - Assay and identity of SN-38 were determined by high-performance liquid chromatography with UV detection at 265 nm. The column used was a Phenomenex Gemini® 5 pm C18 (110 Å, 250 x 4.6 mm) at room temperature. The mobile phase consisted of a 70:30 (v / v) mixture of 10 mM sodium phosphate with 0.1% (v / v) triethylamine, pH 3.5, and acetonitrile. Samples and pharmaceutical product standards of SN-38 were prepared by dissolving the material in a 7:3 (v / v) mixture of acetonitrile and DMSO. Separation was achieved with a flow rate of 1.5 mL / min for a total run time of 8 minutes. Paclitaxel Weight Loading Analysis – The weight loading was determined by comparing a paclitaxel standard curve to a known pharmaceutical concentration using HPLC analysis. Standards were prepared by dissolving paclitaxel in acetonitrile at concentrations of 10, 25, 50, 100, and 200 pg / mL. Paclitaxel pharmaceutical samples were prepared by dissolving the material in the mobile phase at a concentration of 1 mg / mL. The amount of paclitaxel in the pharmaceutical was then converted to a weight percent of the total based on the known amount of pharmaceutical (i.e., 1 mg / mL). SN-38 Weight Loading Analysis – The weight loading was determined by comparing an SN-38 standard curve to a known pharmaceutical concentration using HPLC analysis. Standards were prepared by dissolving SN-38 in a 7:3 (v / v) mixture of acetonitrile and DMSO at concentrations of 50, 100, 200, 300, and 400 pg / mL. Pharmaceutical samples of SN-38 were prepared by dissolving the material in a 7:3 (v / v) mixture of acetonitrile and DMSO at a concentration between 1 and 4 mg / mL, depending on the weight loading. The amount of SN-38 in the pharmaceutical was then converted to a weight percentage of the total based on the known amount of pharmaceutical. Cabazitaxel weight load analysis – the weight load was determined by comparing a cabazitaxel standard curve to a known concentration of pharmaceutical product using analysis of ML / Ί HPLC. Standards were prepared by dissolving cabazitaxel in acetonitrile at concentrations of 20, 40, 60, 80, and 100 pg / mL. Pharmaceutical samples of cabazitaxel were prepared by dissolving the material in the mobile phase at a concentration of 1 mg / mL. The amount of cabazitaxel in the pharmaceutical was then converted to a weight percent of the total based on the known amount of pharmaceutical (i.e., 1 mg / mL). Docetaxel Weight Loading Analysis – The weight loading was determined by comparing a docetaxel standard curve to a known pharmaceutical concentration using HPLC analysis. Standards were prepared by dissolving docetaxel in acetonitrile at concentrations of 10, 50, and 100 pg / mL. Pharmaceutical samples of docetaxel were prepared by dissolving the material in the mobile phase at a concentration of 1 mg / mL. The amount of docetaxel in the pharmaceutical was then converted to a weight percent of the total based on the known amount of pharmaceutical (i.e., 1 mg / mL). Paclitaxel pharmacokinetic experiments in rats – Sprague-Dawley rats (3 males and 3 females per test item) from Hilltop Lab Animals were used by WuXi AppTec for the study. The paclitaxel formulation TYN-21 (100 mg paclitaxel at 13% w / w) was reconstituted in saline (5.2 mL) to provide a solution with a paclitaxel concentration of 2.50 mg / mL. Abraxane was reconstituted with 20 mL of saline according to the package insert to provide a 5 mg / mL paclitaxel solution, which was diluted 1:1 (v / v) with saline to provide a solution with a paclitaxel concentration of 2.5 mg / mL. Both solutions of TYN21 and abraxane were administered at 2.0 mL / kg by rapid IV bolus infusion over 1-2 minutes via the tail vein to deliver a paclitaxel dose of 5.0 mg / kg.Blood samples (±300 pL) were collected from jugular veins into B Microtainer tubes containing K₂EDTA at the end of infusion (EOI), and after 1, 2, 4, and 8 hours. Blood samples were centrifuged at 4°C, 3000 g for 5 minutes within 30 minutes of collection. Plasma was collected in polypropylene tubes or 96-well plates, rapidly frozen on dry ice, and stored at -70 ± 10°C until LC-MS / MS analysis. Quantification was determined by comparing a standard curve (6 non-zero concentrations) of paclitaxel in plasma against the samples from each time point. Abraxane demonstrated an AUC of paclitaxel of 4648 ± 1306 ng*h / mL. The Cmax of paclitaxel from abraxane was 20067 ± 8069 ng / mL. The half-life of abraxane paclitaxel was 3.1 ± 0.6 h. The elimination rate of abraxane paclitaxel was 18.4 ± 5.3 mL / min / kg. TYN-21 demonstrated an AUC of paclitaxel of 5873 ± 2103 ng*h / mL.The Cmax of paclitaxel from TYN-21 was 18367 ± 7410 ng / mL. The half-life of paclitaxel from TYN-21 was 3.2 ± 0.4 h. The elimination rate of paclitaxel from TYN-21 was 15.3 ± 4.6 mL / min / kg. Pharmacokinetic data are shown in Figure 1. Example 1 - Preparation of Sari75-bp-[D-Leu35-co-L-Tyr25] (TFS-1) A jacketed round-bottom flask equipped with a circulating isopropanol / water bath was charged with N,N-dimethylformamide (100 mL). The bath temperature was set at 20°C and stirred for 15 min to equilibrate before the addition of a neopentylamine solution (3.31 mL of 300 mM DMF, 86.6 mg, 1 equiv.) followed by the addition of sarcosine N-carboxyanhydride (20.0 g, 173.8 mmol, 175 equiv.). The sides of the funnel and reaction vessel were rinsed with additional DMF (5 mL). The reaction bath was wrapped in aluminum flake to protect it from light. As the reaction proceeded, the color changed from clear and colorless to a bright orange solution. IR spectroscopy was used to monitor the reaction's progress via the disappearance of carbonyl segments at -1850 and 1778 cm¹. After 8 hours, the reaction was >95% complete but was allowed to proceed overnight (an additional 12 h). The bath temperature was set at 25 °C, and the reaction was then loaded with D-leucine N-carboxyanhydride (5.46 g, 34.77 mmol, 35 equiv.) and L-tyrosine N-carboxyanhydride (5.15 g, 24.84 mmol, 25 equiv.). The consumption of the two NCAs was again monitored via the disappearance of IR carbonyl segments at -1851 and 1785 cm¹ and was complete after 24 h. The reaction mixture was transferred to a laboratory beaker using a small amount of DMF (-5-10 mL) to help.While vigorously stirring with an overhead stirrer, ethyl acetate (480 mL, -4 volumes) was added slowly over 1–2 min. Precipitation was rapid, and noticeable solids began to form after the addition of <1 volume of EtOAc. The precipitate was stirred for 5–10 min to aid in the mechanical breakdown of any large solids, thus helping to leach DMF, which may be trapped within the solids. Stirring was stopped, and the material was allowed to settle before collection via vacuum filtration in a medium-porosity fritted glass funnel. The semi-dried material was briefly resuspended in the frit with an additional 2 volumes (240 mL) of EtOAc. The product was oven-dried under vacuum at 90–100 °C for 2 days to yield 19.8 g (97%) of the title compound as a fine, dense, off-white powder. .1H NMR (DMSOck) δ 9.2-9.0 (30H), 8.6-7.8 (48H), 7.2-6.5 (125H), 4.7-3.7 (845H), 3.0-2.6 (1440H), 1.9-1.2 (104H), 1.0-0.5 (289H); GPC (DMF, 50 mM L¡Br) Mn = 17.6 kDa, Mp = 18.7 kDa, PDI = 1.08. Example 2 - Preparation of Sari75-ú-p-[D-Leu 3o-co-L-Tyr2o] (TFS-2) A jacketed round-bottom flask equipped with a circulating isopropanol / water bath was cooled to 20 °C before the addition of sarcosine N-carboxyanhydride (19.9 g, 172.9 mmol, 175 equiv.), followed by N,N-dimethylformamide (100 mL). The mixture was stirred for <30 seconds before the addition of neopentylamine (3.30 mL of 300 mM DMF, 86.2 mg, 1 equiv.). The reaction vessel was wrapped in aluminum flake to prevent light exposure. After 15–20 min, the reaction began to change from the initial clear, colorless solution to a light orange color that continued to intensify as the reaction proceeded. IR was used to monitor the progression of the reaction via the disappearance of the Sar NCA carbonyl segments at -1850 and 1778 cm⁻¹, with the latter being the preferred wavenumber for monitoring. The reaction was 90% complete after 6 hours but was left to stir overnight.The following day, after a total of 19 hours, the reaction was complete. The circulating bath temperature was increased to 25 °C before the addition of D-leucine N-carboxyanhydride (4.66 g, 29.66 mmol, 30 equiv.) and L-tyrosine N-carboxyanhydride (4.10 g, 19.78 mmol, 20 equiv.). An additional 5 mL of DMF was used to rinse the sides of the funnel and reaction vessel. Significant CO2 gas formation was observed shortly after the reaction was initiated. IR spectroscopy was used to monitor the reaction's progress via the disappearance of D-Leucine NCA and L-Tyrosine NCA carbonyl groups at -1851 and 1785 cor1, with the latter being the preferred wavenumber for monitoring. As the reaction proceeded, the color changed from a bright, clear orange to a light yellow-orange solution that was evident after only a few hours. The reaction was >85% complete after 10 h, and >99.9% complete after 24 h.The reaction mixture (total -125 mL) was transferred to a beaker and fitted with a stir bar. While stirring vigorously, ethyl acetate (250 mL, 2 volumes) was added to precipitate the product. The solids were collected by filtration in a medium-sized fritted glass funnel. The solids were transferred back to the original beaker along with an additional 250 mL of EtOAc and resuspended with vigorous stirring for 20 min. The solids were collected in a new fritted glass funnel, and the same 20-min resuspension procedure was repeated with 250 mL of EtOAc. The product was frit-dried in a vacuum oven at 90-100 °C to produce 15.95 g (84.1%) of the title compound as a fine, whitish, dense powder.1H NMR (DMSO-ofc) δ 9.2-8.9 (21H), 8.6-7.6 (39H), 7.2-6.4 (100H), 4.7-3.7 (694H), 3.1-2.6 (1039H), 1.9 (3H), 1.7-1.2 (33H), 1.0-0.6 (186H); GPC (DMF, 50 mM LiBr) Mn = 16.9 kDa, Mp = 18.0 kDa, PDI = 1.08. Example 3 - Preparation of Sari75-£>-p-[D-Leu3o-co-L-Tyr2o]-Ac (TFS-2-Ac) A round-bottom flask was filled with TFS-2 (500 mg, 0.0261 mmol, 1 equiv.) and N,N-dimethylformamide (5.0 mL), and the mixture was stirred and heated with a heat gun to dissolve the material. Once the reaction mixture cooled to room temperature, triethylamine (36 pL, 0.261 mmol, 10 equiv.) and acetic anhydride (25 pL, 0.261 mmol, 10 equiv.) were added. The reaction was stirred for 24 h before being transferred to a beaker using a minimal amount of N,N-dimethylformamide (~1.5 mL) to aid in the transfer. With vigorous stirring, a large excess of ethyl acetate (40 mL) was added for 1 min. The precipitate was stirred for 5 min before the solids were collected in a fritted glass funnel. The product was washed in the funnel with additional ethyl acetate (2 x 40 mL) and then dried at 95 °C for 48 h to produce the title compound as a white granular powder (320 mg, 64.0%).1H NMR (DMSO-ofc) δ 9.2-9.0 (16H), 8.8-7.5 (54H), 7.5-6.4 (100H), 4.7-3.7 (843H), 3.22.6 (1272H), 2.2 (24H), 1.8-1.0 (96H), 1.0-0.4 (211H). Example 4 - Preparation of Sari25-í>-p-[D-Glu(OBn)15-co-L-Glu(OBn)i5] Follow the general procedure of Example 1 with the following reagent equivalents and quantities: neopentylamine (30 mg, 1 equiv.), sarcosine NCA (4.95 g, 125 equiv.), D-Glu(OBn) NCA (1.36 g, 15 equiv.), and L-Glu(OBn) (1.36 g, 15 equiv.). This yielded the title compound as a light yellow solid (4.6 g, 86%). GPC (DMF, 50 mM LiBr) Mn = 13.9 kDa, Mp = 14.9 kDa, PDI = 1.15. Example 5 - Preparation of Sari25-bp-[D-Glu(OBn)2o-co-L-Glu(OBn)2o] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (30 mg, 1 equiv.), sarcosine NCA (4.95 g, 125 equiv.), D-Glu(OBn) NCA (1.81 g, 20 equiv.), and L-Glu(OBn) (1.81 g, 20 equiv.). This yielded the title compound as a light yellow solid (4.9 g, 80%). GPC (DMF, 50 mM LiBr) Mn = 14.6 kDa, Mp = 15.6 kDa, PDI = 1.11. Example 6 - Preparation of Sari25-bp-[D-Phei5-co-L-Tyri5] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (30 mg, 1 equiv.), sarcosine NCA (4.95 g, 125 equiv.), D-Phe NCA (0.987 g, 15 equiv.), and L-Tyr (1.07 g, 15 equiv.). This yielded the title compound as a light yellow solid (3.9 g, 83%). GPC (DMF, 50 mM LiBr) Mn = 13.7 kDa, Mp = 14.5 kDa, PDI = 1.03. Example 7 - Preparation of Sari25-hp-[D-Leu2o-co-L-Tyri5] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (30 mg, 1 equiv.), sarcosine NCA (4.95 g, 125 equiv.), D-Leu NCA (1.08 g, 20 equiv.), and L-Tyr (1.07 g, 15 equiv.). This yielded the title compound as a light yellow solid (3.7 g, 79%). GPC (DMF, 50 mM LiBr) Mn = 15.1 kDa, Mp = 16.1 kDa, PDI = 1.09. Example 8 - Preparation of Sari75-bp-[D-Glu(OBn)25-co-L-Glu(OBn)25] Follow the general procedure of Example 1 with the following reagent equivalents and quantities: neopentylamine (43 mg, 1 equiv.), sarcosine NCA (10.0 g, 175 equiv.), D-Glu(OBn) NCA (3.27 g, 25 equiv.), and L-Glu(OBn) (3.27 g, 25 equiv.). This yielded the title compound as a light yellow solid (10 g, 86%). GPC (DMF, 50 mM LiBr) Mn = 15.9 kDa, Mp = 16.9 kDa, PDI = 1.06. Example 9 - Preparation of Sari75-bp-[D-Phe2o-co-L-Tyr20] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (43 mg, 1 equiv.), sarcosine NCA (10.0 g, 175 equiv.), D-Phe NCA (1.90 g, 20 equiv.), and L-Tyr (2.06 g, 20 equiv.). This yielded the title compound as a light yellow solid (7.8 g, 85%). GPC (DMF, 50 mM LiBr) Mn = 14.9 kDa, Mp = 15.9 kDa, PDI = 1.04. Example 10 - Preparation of Sari75-6-p-[Sario-co-L-Tyr5o] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (43 mg, 1 equiv.), sarcosine NCA (first block, 10.0 g, 175 equiv.), sarcosine NCA (0.57 g, 10 equiv.), and L-Tyr (5.14 g, 50 equiv.). This yielded the title compound as a light yellow solid (10.1 g, 96%). GPC (DMF, 50 mM LiBr) Mn = 15.5 kDa, Mp = 16.4 kDa, PDI = 1.15. Example 11 - Preparation of Sari75-6-p-[D-Phe25-co-L-Glu(OBn)25] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (21.7 mg, 1 equiv.), sarcosine NCA (4.98 g, 175 equiv.), D-Phe NCA (1.19 g, 25 equiv.), and L-Glu(OBn) (1.64 g, 25 equiv.). This yielded the title compound as a light yellow solid (3.8 g, 71%). GPC (DMF, 50 mM LiBr) Mn = 16.3 kDa, Mp = 17.4 kDa, PDI = 1.09. Example 12 - Preparation of Sari75-í>-p-[D-Phe3o-co-L-Tyri0] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (21.7 mg, 1 equiv.), sarcosine NCA (4.98 g, 175 equiv.), D-Phe NCA (1.43 g, 30 equiv.), and L-Tyr (0.515 g, 10 equiv.). This yielded the title compound as a light yellow solid (4.26 g, 92.4%). GPC (DMF, 50 mM LiBr) Mn = 15.9 kDa, Mp = 16.9 kDa, PDI = 1.60. Example 13 - Preparation of Sari75-£>-p-[D-Pheio-co-L-Tyr3o] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (21.7 mg, 1 equiv.), sarcosine NCA (4.98 g, 175 equiv.), D-Phe NCA (0.475 g, 10 equiv.), and L-Tyr (1.54 g, 30 equiv.). This yielded the title compound as a light yellow solid (4.66 g, 99.3%). GPC (DMF, 50 mM LiBr) Mn = 16.1 kDa, Mp = 17.1 kDa, PDI = 1.07. Example 14 - Preparation of Sari75-6-p-[D-Phe25-co-L-Tyri5] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (21.7 mg, 1 equiv.), sarcosine NCA (5.0 g, 175 equiv.), D-Phe NCA (1.19 g, 25 equiv.), and L-Tyr (0.772 g, 15 equiv.). This produced the title compound as a light yellow solid (4.37 MA / 1 g, 94.35%). GPC (DMF, 50 mM LiBr) Mn = 14.1 kDa, Mp = 15.0kDa, PDI = 1.54. Example 15 - Preparation of Sari75-ó-p-[D-Phei5-co-L-Tyr25] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (21.7 mg, 1 equiv.), sarcosine NCA (5.0 g, 175 equiv.), D-Phe NCA (0.712 g, 15 equiv.), and L-Tyr (1.29 g, 25 equiv.). This yielded the title compound as a light yellow solid (4.57 g, 97.7%). GPC (DMF, 50 mM LiBr) Mn = 14.4 kDa, Mp = 15.3 kDa, PDI = 1.07. Example 16- Preparation of Sar2io-f>-p-[D-Pheis-co-L-Tyr25] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (18 mg, 1 equiv.), sarcosine NCA (5.0 g, 210 equiv.), D-Phe NCA (0.593 g, 15 equiv.), and L-Tyr (1.07 g, 25 equiv.). This yielded the title compound as a light yellow solid (3.43 g, 78.0%). GPC (DMF, 50 mM LiBr) Mn = 17.0 kDa, Mp = 18.1 kDa, PDI = 1.06. Example 17 - Preparation of Sar2io-ó-p-[D-Pheio-co-L-Tyr3o] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (18 mg, 1 equiv.), sarcosine NCA (5.0 g, 210 equiv.), D-Phe NCA (0.396 g, 10 equiv.), and L-Tyr (1.29 g, 30 equiv.). This yielded the title compound as a light yellow solid (3.62 g, 82.0%). GPC (DMF, 50 mM LiBr) Mn = 17.0 kDa, Mp = 18.1 kDa, PDI = 1.08. Example 18 - Preparation of Sar2i0-bp-[D-Phe5-co-L-Tyr35] Follow the general procedure of Example 1 with the following reagent equivalents and amounts: neopentylamine (18 mg, 1 equiv.), sarcosine NCA (5.0 g, 210 equiv.), D-Phe NCA (0.198 g, 5 equiv.), and L-Tyr (1.50 g, 35 equiv.). This yielded the title compound as a light yellow solid (3.64 g, 82.2%). GPC (DMF, 50 mM LiBr) Mn = 16.8 kDa, Mp = 17.8 kDa, PDI = 1.13. Example 19 - Preparation of Sar235-bp-[D-Pheio-co-L-Tyr30] (TFS-3) A jacketed round-bottom flask equipped with a circulating isopropanol / water bath was cooled to 20 °C before the addition of sarcosine N-carboxyanhydride (15.0 g, 130.5 mmol, 235 equiv.), followed by N,N-dimethylformamide (75 mL). The mixture was stirred for <30 seconds before the addition of neopentylamine (1.85 mL of 300 mM DMF, 48.4 mg, 0.555 mmol, 1 equiv.). The reaction vessel was wrapped in aluminum flake to prevent light exposure. After 15–20 min, the reaction began to change from the initial clear, colorless solution to a light orange color that continued to intensify as the reaction proceeded. IR was used to monitor reaction progression via the disappearance of the Sar NCA carbonyl segments at ~1850 and 1778 cm1, with the latter being the preferred wavenumber for monitoring. The reaction was completed the following day, after a total of 22 h.The circulating bath temperature was increased to 25 °C before the addition of D-phenylalanine N-carboxyanhydride (1.06 g, 5.55 mmol, 10 equiv.) and L-tyrosine N-carboxyanhydride (3.45 g, 16.7 mmol, 30 equiv.). Additional DMF (~5 mL) was used to rinse the sides of the funnel and reaction vessel. Significant CO2 gas formation was observed shortly after the reaction began. IR spectroscopy was used to monitor the reaction's progress via the disappearance of the carbonyl stretches of D-Phe NCA and L-Tyr NCA at ~1847 and 1786 cm1, with the latter being the preferred wavenumber for monitoring. As the reaction proceeded, the color changed from a bright light orange to a pale yellow-orange solution, which was evident after only a few hours. The reaction was complete after a total of 30 h. The reaction mixture (total of ~100 mL) was transferred to a laboratory beaker and equipped with a top stirrer.While vigorously stirring, ethyl acetate (400 mL, 4 volumes) was added to precipitate the product. The solids were collected by filtration in a medium fritted glass funnel, and the semi-dried material was then transferred back to the original beaker with additional EtOAc (200 mL, 2 volumes) and a suspension was formed by vigorous stirring for 20 min. The solids were collected in the same glass funnel and washed once more with an additional EtOAc (100 mL, 1 volume). The product was dried in a vacuum oven at 90-100 °C for 2 days to produce 11.3 g (87.9%) of the title compound as a fine off-white powder.1H NMR (DMSO-cfe) δ 9.3-9.0 (28H), 8.5-7.8 (45H), 7.4-6.4 (170H), 4.6-3.6 (784H), 3.2-2.5 (1326H), 1.9 (5H), 1.2-1.1 (6H), 0.9-0.8 (14H); GPC (DMF, 50 mM LiBr) Mn = 18.1 kDa, Mp = 19.3 kDa, PDI = 1.07. Example 20 - Preparation of Sar235-í>-p-[D-Phei5-co-L-Tyr25] Follow the general procedure of Example 19 with the following reagent equivalents and amounts: neopentylamine (16.1 mg, 1 equiv.), sarcosine NCA (5.0 g, 235 equiv.), D-Phe NCA (0.531 g, 15 equiv.), and L-Tyr (0.959 g, 25 equiv.). This yielded the title compound as a cream-colored solid (3.24 g, 75.9%). GPC (DMF, 50 mM LiBr) Mn = 17.1 kDa, Mp = 18.2 kDa, PDI = 1.07. Example 21 - Preparation of Sar235-£>-p-[D-Phe5-co-L-Tyr35] Follow the general procedure of Example 19 with the following reagent equivalents and amounts: neopentylamine (16.1 mg, 1 equiv.), sarcosine NCA (5.0 g, 235 equiv.), D-Phe NCA (0.177 g, 5 equiv.), and L-Tyr (1.34 g, 35 equiv.). This yielded the title compound as a cream-colored solid (3.89 g, 90.5%). GPC (DMF, 50 mM LiBr) Mn = 17.0 kDa, Mp = 18.1 kDa, PDI = 1.10. Example 22 - Feeding 30% paclitaxel with TFS-2 2.0 g of TFS-2 (poly(Sar)175-b / oq17e-poly(c / -Leuso-co-Tyr2o)) and 2.0 g of trehalose were dissolved in 90 mL of 30:70 (v / v) tert-butanol:water to produce a solution of 22.2 mg / mL of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (603 mg) was dissolved in 30 mL of tert-butanol using an ultrasonic water bath to produce a solution of 20.1 mg / mL. The two solutions were mixed and stirred for 15 minutes before being filtered through a 0.22 µm PVDF filter. The formulation solution was then transferred to 20 mL vials in 10 mL aliquots per vial, frozen at -80 °C, and then lyophilized for 2 days. This yielded 4.2 g of a fragmented white cake containing paclitaxel at a weight loading of 12.9%. Example 23 - Feeding 15% paclitaxel with TFS-2 100 mg of TFS-2 (poly(Sar)175-t> / oque-poly(d-Leu3o-co-Tyr2o)) and 100 mg of trehalose were dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 10 mg / mL solution of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (15 mg) was dissolved in 0.75 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes before being filtered through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C and then lyophilized for 2 days. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight load of 7.51%. Example 24 - Feeding 15% paclitaxel with TFS-1 Use the general method of Example 23 with the following exception: the copolymer used was TFS1 (poly(Sar)i75-o / ogt / e-poly(d-Leu35-co-Tyr25)). This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 6.90%. Example 25 - Feeding 20% ​​paclitaxel with TFS-2 Use the general method of Example 23 with the following exception: the drug solution consisted of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 9.33%. Example 26 - Feeding 20% ​​paclitaxel with TFS-1 Use the general method of Example 23 with the following exceptions: the copolymer used was TFS-1 (poly(Sar)175-b / oque-poly(cy-Leu35-co-Tyr25)); and the drug solution consisted of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 9.20%. Example 27 - Feeding 25% paclitaxel with TFS-2. 50 mg of TFS-2 (poly(Sar)175-b / oq¿7e-pol¡(c / -Leu3o-co-Tyr2o)) and 50 mg of trehalose were dissolved in 5 mL of 40:60 (v / v) tert-butanol:water to produce a 10 mg / mL solution of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (12.5 mg) was dissolved in 0.625 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes before filtering through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C, and then lyophilized for 2 days. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 11.4%. Example 28 - Feeding 30% paclitaxel with TFS-2 Use the general method of Example 27 with the following exception: the drug solution consisted of 15 mg of paclitaxel dissolved in 0.75 mL of tert-butanol. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 14.6%. Example 29 - Feeding 25% paclitaxel (at 4 mg / mL) with TFS-2 100 mg of TFS-2 (poly(Sar)175-b / oque-poly(c / -Leu3o-co-Tyr2o)) and 100 mg of trehalose were dissolved in 5 mL of 35:65 (v / v) tert-butanol:water to produce a 20 mg / mL solution of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (25 mg) was dissolved in 1.25 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes to produce a paclitaxel concentration of 4 mg / mL, which was then filtered through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C, and then lyophilized for 2 days. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 9.9%. Example 30 - Feeding 30% paclitaxel (at 4 mg / mL) with TFS-2 Use the general method of Example 29 with the following exceptions: 100 mg of TFS-2 (poly(Sar)i75-t> / ogt / e-poly(c / -Leu30-co-Tyr20)) and 100 mg of trehalose were dissolved in 6 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 16.7 mg / mL of each component; and the drug solution consisted of 30 mg of paclitaxel dissolved in 1.5 mL of tert-butanol. This produced the drug product as a fragmented white cake containing paclitaxel at a weight loading of 11.7%. Example 31 - Feeding 35% paclitaxel (at 4 mg / mL) with TFS-2 Use the general method of Example 29 with the following exceptions: 100 mg of TFS-2 (poly(Sar)i75-?> / oque-poly(c / -Leu3o-co-Tyr2o)) and 100 mg of trehalose were dissolved in 7 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 14.3 mg / mL of each component; and the drug solution consisted of 35 mg of paclitaxel dissolved in 1.75 mL of tert-butanol. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 14.3%. Example 32 - Feeding 25% paclitaxel (at 5 mg / mL) with TFS-2 100 mg of TFS-2 (pol(Sar)175-β2-pol(c-Leu3O-c-Tyr2O)) and 100 mg of trehalose were dissolved in 3.75 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 26.7 mg / mL of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (25 mg) was dissolved in 1.25 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes to produce a solution with a paclitaxel concentration of 5 mg / mL, which was then filtered through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C and then lyophilized for 2 days. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 10.2%. Example 33 - Feeding 30% paclitaxel (at 5 mg / mL) with TFS-2 Use the general method of Example 32 with the following exceptions: 100 mg of TFS-2 (poly(Sar)i75-t> / oqt / e-poly(cy-Leu3o-co-Tyr2o)) and 100 mg of trehalose were dissolved in 4.5 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 22.2 mg / mL of each component; and the drug solution consisted of 30 mg of paclitaxel dissolved in 1.5 mL of tert-butanol. This produced the drug product as a fragmented white cake containing paclitaxel at a weight loading of 11.5%. Example 34 - Feeding 35% paclitaxel (at 5 mg / mL) with TFS-2 Use the general method of Example 32 with the following exceptions: 100 mg of TFS-2 (poly(Sar)i75-b / ogtte-poly(c / -Leu3o-co-Tyr2o)) and 100 mg of trehalose were dissolved in 5.25 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 19.0 mg / mL of each component; and the drug solution consisted of 35 mg of paclitaxel dissolved in 1.75 mL of tert-butanol. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight loading of 13.1%. Example 35 - Feeding 2.5% paclitaxel with Sari25-bp-[D-Glu(OBn)i5-co-LGlu(OBn)i5] and without cryoprotectant 200 mg of poly(Sar)125-b / oq1 / e-pol1[(c / -Glu(OBn)15-co-L-Glu(OBn)15] was dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 20 mg / mL solution of the polymer. Separately, paclitaxel (5 mg) was dissolved in 0.25 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes and then filtered through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C and then lyophilized for 2 days. This yielded the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 3.0%. Example 36 - Feeding 5.0% paclitaxel with Sari25-bp-[D-Glu(OBn)i5-co-LGlu(OBn)ib] and without cryoprotectant Use the general method of Example 35 with the following exceptions: The pharmaceutical substance solution consisted of 10 mg of paclitaxel dissolved in 0.5 mL of tert-butanol, which was added to the polymer solution. This produced the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 6.3%. Example 37 - Feeding 10.0% paclitaxel with Sari25-o-p-[D-Glu(OBn)i5-co-LGlu(OBn)i5] and without cryoprotectant Use the general method of Example 35 with the following exceptions: The pharmaceutical substance solution consisted of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol, which was added to the polymer solution. This produced the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 11.1%. Example 38 - Feeding 2.5% paclitaxel with Sari25-o-p-[D-Glu(OBn)i5-co-LGlu(OBn)i5] 100 mg of poly(Sar)i25-b / oque-poly[c / -Glu(OBn)i5-co-L-Glu(OBn)i5] and 100 mg of trehalose were dissolved in 5 mL of 40:60 (v / v) tert-butanol:water to produce a 20 mg / mL solution of each component. Separately, paclitaxel (2.5 mg) was dissolved in 0.125 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes and then filtered through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C and then lyophilized for 2 days. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight load of 1.6%. Example 39 - Feeding 5% paclitaxel with Sari25-bp-[D-Glu(OBn)i5-co-L-Glu(OBn)i5] Use the general method of Example 38 with the following exceptions: The pharmaceutical substance solution consisted of 5.0 mg of paclitaxel dissolved in 0.25 mL of tert-butanol, which was added to the polymer solution. This produced the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 1.9%. Example 40 - Feeding 10% paclitaxel with Sari25-hp-[D-Glu(OBn)i5-co-LGlu(OBn)i5] Use the general method of Example 38 with the following exceptions: The pharmaceutical substance solution consisted of 10.0 mg of paclitaxel dissolved in 0.5 mL of tert-butanol, which was added to the polymer and trehalose solution. This produced the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 4.1%. Example 41 - Feeding 2.5% paclitaxel with Sari25-o-p-[D-Glu(OBn)2o-co-LGlu(OBn)2o] and without cryoprotectant 200 mg of poly(Sar)125-β-poly[d-Glu(OBn)20-co-L-Glu(OBn)20] was dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 20 mg / mL solution of the polymer. Separately, paclitaxel (5 mg) was dissolved in 0.25 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes and then filtered through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C and then lyophilized for 2 days. This yielded the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 2.7%. Example 42 - Feeding 5.0% paclitaxel with Sari25-bp-[D-Glu(OBn)20-co-LGlu(OBn)20] and without cryoprotectant Use the general method of Example 41 with the following exceptions: The pharmaceutical substance solution consisted of 10 mg of paclitaxel dissolved in 0.5 mL of tert-butanol, which was added to the polymer solution. This produced the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 5.1%. Example 43 - Feeding 10% paclitaxel with Sari25-bp-[D-Glu(OBn)2o-co-LGlu(OBn)20] and without cryoprotectant Use the general method of Example 41 with the following exceptions: The pharmaceutical substance solution consisted of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol, which was added to the polymer solution. This produced the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 8.3%. Example 44 - Feeding 2.5% paclitaxel with Sar125-£>-p-[D-Glu(OBn)2o-co-LGlu(OBn)20] 100 mg of poly(Sar)i25-b / oqL / e-poly[d-Glu(OBn)2o-co-L-Glu(OBn)2o] and 100 mg of trehalose were dissolved in 5 mL of 40:60 (v / v) tert-butanol:water to produce a 20 mg / mL solution of each component. Separately, paclitaxel (2.5 mg) was dissolved in 0.125 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes and then filtered through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C and then lyophilized for 2 days. This produced the pharmaceutical product as a fragmented white cake containing paclitaxel at a weight load of 1.4%. Example 45 - Feeding 5% paclitaxel with Sari25-bp-[D-Glu(OBn)2o-co-L-Glu(OBn)2o] Use the general method of Example 44 with the following exceptions: The pharmaceutical substance solution consisted of 5.0 mg of paclitaxel dissolved in 0.25 mL of ferc-butanol, which was added to the polymer and trehalose solution. This produced the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 2.5%. Example 46 - Feeding 10% paclitaxel with Sari25-bp-[D-Glu(OBn)2o-co-LGlu(OBn)20] Use the general method of Example 44 with the following exceptions: The pharmaceutical substance solution consisted of 10.0 mg of paclitaxel dissolved in 0.5 mL of tert-butanol, which was added to the polymer and trehalose solution. This produced the pharmaceutical product as a white solid containing paclitaxel at a weight loading of 4.3%. Example 47 - Feeding SN-38 at 15% with TSF-3 Trehalose (8.0 g) was dissolved in 400 mL of water before the addition of 2.0 g of TFS-3 (Sar23s[DPheio-co-Tyrao]) to produce a solution of 20 mg / mL trehalose and 5 mg / mL TFS-3. The resulting solution was stirred for 1 hour before filtering through a 0.5 µm polypropylene filter. Separately, an SN-38 solution was prepared by dissolving 281 mg in 3.75 mL of DMSO, with the aid of heat, to produce a 75 mg / mL stock solution. While 375 mL of the polymer / trehalose solution was being shear-mixed with a homogenizer at 10,000 RPM, the SN-38 stock solution was added, and mixing continued for 1 minute. The resulting homogeneous emulsion was processed in two steps through a microfluidizer with an inlet pressure of 100 PSI (689.47 kPa) and an operating pressure of approximately 25,000 PSI (1723.The extruded solution was extruded at 69 kPa through an auxiliary processing chamber followed by a 50 µm interaction chamber with the outlet tube cooled in an ice bath. The extruded solution was then diafiltered against 2.5 L of 20 mg / mL trehalose using a tangential flow filtration system equipped with an mPES hollow fiber filter (10 kDa MWCO, 790 cm² surface area) at a flow rate of 300 mU / min. The solution was then concentrated to approximately 1 / 4 the original volume so that the final polymer concentration was approximately 20 mg / mL. The formulation solution was then filtered through a 0.2 µm PES filter with a surface area of ​​20 cm². The filtered solution was frozen at -80 °C and lyophilized for 2 days. This produced the pharmaceutical formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 5.73%. Example 48 - Feeding SN-38 at 20% with TSF-3 Use the general method of Example 47 with the following exception: a total of 5.0 mL of the SN-38 solution (75 mg / mL) was homogenized with 375 mL of the polymer / trehalose solution. This produced the pharmaceutical product as a slightly yellow, fragmented cake with an SN38 weight loading of 7.54%. Example 49 - Feeding SN-38 at 25% with TSF-3 Use the general method of Example 47 with the following exception: a total of 6.25 mL of the SN-38 solution (75 mg / mL) was homogenized with 375 mL of the polymer / trehalose solution. This produced the pharmaceutical product as a slightly yellow, fragmented cake with an SN-38 weight loading of 9.35%. Example 50 - Feeding SN-38 at 30% with TSF-3 Use the general method of Example 47 with the following exception: a total of 7.5 mL of the SN-38 solution (75 mg / mL) was homogenized with 375 mL of the polymer / trehalose solution. This produced the pharmaceutical product as a slightly yellow, fragmented cake with an SN38 weight loading of 11.64%. Example 51 - Feeding SN-38 at 40% with TSF-3 Use the general method of Example 47 with the following exception: a total of 10.0 mL of the SN-38 solution (75 mg / mL) was homogenized with 375 mL of the polymer / trehalose solution. This produced the pharmaceutical product as a slightly yellow, fragmented cake with a weight loading SN-38 ΜΛ / ΙΖ / ΖυΖΖ / υθ4ΖΟΊ of 14.80% Example 52 - Feeding SN-38 at 10% with Sari75-¿-p-[D-Phe25-co-L-Glu(OBn)25] Trehalose (750 mg) was dissolved in 150 mL of water before the addition of 750 mg of Sari75-bp-[DPhe25-co-L-Glu(OBn)2s] to produce a 5 mg / mL solution of each component. Separately, an SN-38 solution was prepared by dissolving 75 mg in 1.0 mL of DMSO, with the aid of heat, to produce a 75 mg / mL stock solution. While shearing the polymer / trehalose solution with a homogenizer at 10,000 RPM, the SN-38 stock solution was added, and mixing continued for 1 minute. The resulting homogeneous emulsion was processed through a microfluidizer with an inlet pressure of 100 PSI (689.47 kPa) and an operating pressure of approximately 25,000 PSI (1723.69 kPa) via an auxiliary processing chamber followed by a 50 pm X interaction chamber with the outlet tube cooled in an ice-water bath. The extruded solution was then diafiltered against 1.Two µL of 5 mg / mL trehalose were filtered using a tangential flow filtration system equipped with an mPES hollow fiber filter (10 kDa MWCO, 790 cm² surface area) at a flow rate of 300 mL / min. Half of the formulation solution was frozen at -80 °C and lyophilized for 2 days. The other half of the formulation was filtered through a 0.2 µm PES filter, frozen at -80 °C, and lyophilized for 2 days. Estro produced the pharmaceutical formulations as slightly yellow, fragmented cakes with an SN-38 weight loading of 2.8% for the unfiltered formulation and 0.3% for the filtered formulation. Example 53 - Feeding SN-38 at 10% with Sari75-6-p-[D-Pheio-co-L-Tyr3o] Use the general method of Example 52 with the following exception: the polymer used was Sari7sb-p-[D-Pheio-co-L-Tyr3o]. Estro produced the pharmaceutical formulations as slightly yellow, fragmented cakes, with an SN-38 weight loading of 4.2% for the unfiltered formulation and 4.1% for the filtered formulation. Example 54 - Feeding SN-38 at 10% with Sari75-bp-[D-Phe25-co-L-Tyri5] Use the general method of Example 52 with the following exception: the polymer used was Sarvsb-p-[D-Phe25-co-L-Tyri5]. This produced the pharmaceutical formulations as slightly yellow, fragmented cakes, with an SN-38 weight loading of 4.1% for the unfiltered formulation and 0.5% for the filtered formulation. Example 55 - Feeding SN-38 at 10% with Sari75-6-p-[D-Phei5-co-L-Tyr25] Use the general method of Example 52 with the following exception: the polymer used was Sarvsb-p-[D-Phe i5-co-L-Tyr2s]. This produced the pharmaceutical formulations as slightly yellow, fragmented cakes, with an SN-38 weight loading of 3.9% for the unfiltered formulation and 2.8% for the filtered formulation. Example 56 - Feeding SN-38 at 15% with Sar2io-hp-[D-Phei5-co-L-Tyr25] Trehalose (1.0 g) was dissolved in 200 mL of water before the addition of 1.0 g of Sar2io-bp-[D-Pheisco-L-Tyr2s] to produce a 5 mg / mL solution of each component. Separately, an SN-38 solution was prepared by dissolving 150 mg in 2.0 mL of DMSO, with the aid of heat, to produce a 75 mg / mL stock solution. While shearing the polymer / trehalose solution with a homogenizer at 10,000 RPM, the SN-38 stock solution was added, and mixing continued for 1 minute. The resulting homogeneous emulsion was processed through a microfluidizer with an inlet pressure of 100 PSI (689.47 kPa) and an operating pressure of approximately 25,000 PSI (1723.69 kPa) through an auxiliary processing chamber followed by a 50 pm X interaction chamber with the outlet tube cooled in an ice water bath.Approximately 120 mL of the extruded solution was then diafiltered against 600 mL of 5 mg / mL trehalose using a tangential flow filtration system equipped with an mPES hollow fiber filter (10 kDa MWCO, 790 cm² surface area) at a flow rate of 300 mL / min. The formulation was filtered through a 0.45 µm PVDF filter and then through a 0.2 µm PES filter, frozen at -80 °C, and lyophilized for 2 days. This yielded the pharmaceutical formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 5.0%. Example 57 - Feeding SN-38 at 15% with Sari75-bp-[D-Pheio-co-L-Tyr3o] Use the general method of Example 56 with the following exception: the polymer used was Sari75b-p-[D-Phew-co-L-Tyr3o]. This produced the pharmaceutical formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 4.9%. Example 58 - Feeding SN-38 at 15% with Sari75-6-p-[D-Phe5-co-L-Tyr35] Use the general method of Example 56 with the following exception: the polymer used was Sarvsb-HD-Phes-co-L-Tyrss. This produced the pharmaceutical formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 2.9%. Example 59 - Feeding SN-38 at 10% with Sar2io-bp-[D-Phei5-co-L-Tyr25] Trehalose (1.0 g) was dissolved in 200 mL of water before the addition of 1.0 g of Sar2io-bp-[D-Pheisco-L-Tyrzs] to produce a 5 mg / mL solution of each component. The polymer / trehalose solution was heated to 65 °C for 30 min to aid dissolution. Separately, an SN-38 solution was prepared by dissolving 100 mg in 1.33 mL of DMSO, with the aid of heat, to produce a 75 mg / mL stock solution. While shearing the polymer / trehalose solution with a homogenizer at 10,000 RPM, the SN-38 stock solution was added, and mixing continued for 1 min. The resulting homogeneous emulsion was processed through a microfluidizer with an inlet pressure of 100 PSI (689.47 kPa) and an operating pressure of approximately 25,000 PSI (1723.69 kPa) through an auxiliary processing chamber followed by a 50 pm X interaction chamber with the outlet tube cooled in an ice water bath.Approximately 120 mL of the extruded solution was then diafiltered against 600 mL of 5 mg / mL trehalose using a tangential flow filtration system equipped with an mPES hollow fiber filter (10 kDa MWCO, 790 cm² surface area) at a flow rate of 300 mL / min. The formulation was filtered through a 0.45 µm PVDF filter and then through a 0.2 µm PES filter, frozen at -80 °C, and lyophilized for 2 days. This yielded the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 3.8%. Example 60 - Feeding SN-38 at 10% with Sar2io-bp-[D-Pheio-co-L-Tyr30] Use the general method of Example 59 with the following exception: the polymer used was Sar2ioMA / 1 bp-[D-Pheio-co-L-Tyr3o]. This produced the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 3.4%. Example 61 - Feeding SN-38 at 15% with Sar2io-í>-p-[D-Phei5-co-L-Tyr25] Trehalose (1.0 g) was dissolved in 200 mL of water before the addition of 1.0 g of Sar2io-bp-[D-Phei5co-L-Tyrzs] to produce a 5 mg / mL solution of each component. The polymer / trehalose solution was stirred overnight to aid dissolution and then filtered through a 0.2 µm PES filter. Separately, an SN-38 solution was prepared by dissolving 150 mg in 2.0 mL of DMSO, with the aid of heat, to produce a 75 mg / mL stock solution. While shearing the polymer / trehalose solution with a homogenizer at 10,000 RPM, the SN-38 stock solution was added, and mixing continued for 1 minute. The resulting homogeneous emulsion was processed through a microfluidizer with an inlet pressure of 100 PSI (689.47 kPa) and an operating pressure of approximately 25,000 PSI (1723.69 kPa) through an auxiliary processing chamber followed by a 50 pm X interaction chamber with the outlet tube cooled in an ice-water bath. Approximately 120 mL of the extruded solution was then diafiltered against 600 mL of 5 mg / mL trehalose using a tangential flow filtration system equipped with an mPES hollow fiber filter (10 kDa MWCO, 790 cm² surface area) at a flow rate of 300 mL / min. The formulation was filtered through a 0.45 pm PVDF filter and then through a 0.2 pm PES filter, frozen at -80 °C, and lyophilized for 2 days. This yielded the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 1.4%. Example 62 - Feeding SN-38 at 15% with Sar210-dp-[D-Pheio-co-L-Tyr30] Use the general method of Example 61 with the following exception: the polymer used was Saríiob-p-[D-Pheio-co-L-Tyr3o]. This produced the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 3.0%. Example 63 - Feeding SN-38 at 15% with Sar235-bp-[D-Phei5-co-L-Tyr25] Use the general method of Example 61 with the following exception: the polymer used was Sar 235 bp-[D-Phe 15 -co-L-Tyr 25]. This produced the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 1.6%. Example 64 - Feeding SN-38 at 15% with TFS-3 (Sar235-bp-[D-Pheio-co-L-Tyr30]) Use the general method of Example 61 with the following exception: the polymer used was TFS-3 (Sar 235-¿>-p-[D-Pheio-co-L-Tyr3o]). This produced the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 3.7%. Example 65 - Feeding SN-38 at 6% with Sar235-dp-[D-Phei5-co-L-Tyr25] Trehalose (1.0 g) was dissolved in 200 mL of water before the addition of 1.0 g of Sar 235-bp-[DPhei5-co-L-Tyr2s] to produce a 5 mg / mL solution of each component. The polymer / trehalose solution was stirred overnight to aid in dissolution and then filtered through a 0.8 / 0.45 pm PES filter. Separately, an SN-38 solution was prepared by dissolving 45 mg in 0.6 mL of DMSO, with the aid of heat, to produce a 75 mg / mL stock solution. While shear-mixing 150 mL of the filtered polymer / trehalose solution with a homogenizer at 10,000 RPM, the SN-38 stock solution was added, and mixing continued for 1 minute. The resulting homogeneous emulsion was processed through a microfluidizer with an inlet pressure of 100 PSI (689.47 kPa) and an operating pressure of approximately 25,000 PSI (1723.69 kPa) through an auxiliary processing chamber followed by a 50 pm X interaction chamber with the outlet tube cooled in an ice-water bath. Approximately 120 mL of the extruded solution was then diafiltered against 600 mL of 5 mg / mL trehalose using a tangential flow filtration system equipped with an mPES hollow fiber filter (10 kDa MWCO, 790 cm² surface area) at a flow rate of 300 mL / min. The formulation was filtered through a 0.45 pm PVDF filter and then through a 0.2 pm PES filter, frozen at -80 °C, and lyophilized for 2 days. This yielded the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 2.02%. Example 66 - Feeding SN-38 at 8% with Sar235-o-p-[D-Phei5-co-L-Tyr25] Use the general method of Example 65 with the following exception: the SN-38 solution consisted of 60 mg dissolved in 0.8 mL of DMSO. This produced the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 2.49%. Example 67 - Feeding SN-38 at 6% with TFS-3 (Sar235-o-p-[D-Pheio-co-L-Tyr3o]) Use the general method of Example 65 with the following exception: the polymer used was TFS-3 (Sar 235-¿>-p-[D-Pheio-co-L-Tyr3o]). This produced the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 2.35%. Example 68 - Feeding SN-38 at 8% with TFS-3 (Sar235-o-p-[D-Pheio-co-L-Tyr3o]) Use the general method of Example 65 with the following exception: the polymer used was TFS-3 (Sar235-bp-[D-Pheio-co-L-Tyr3o]), and the SN-38 solution consisted of 60 mg dissolved in 0.8 mL of DMSO. This produced the drug formulation as a slightly yellow, fragmented cake with an SN-38 weight loading of 2.88%. Example 69 - Feeding cabazitaxel 15% with (Sari75-£>-p-[D-Leu20-co-L-Tyri5] 100 mg of poly(Sar)125-β-oque-poly(d-Leu20-co-Tyri5) and 100 mg of trehalose were dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 10 mg / mL solution of each component. Separately, cabazitaxel (15 mg) was dissolved in 1.65 mL of 13% (v / v) DMSO in tert-butanol using an ultrasonic water bath to produce a 9 mg / mL solution. The two solutions were mixed and stirred for 15 minutes and then filtered through a 0.22 µm PVDF filter. The formulation solution was frozen at -80 °C and then lyophilized for 2 days. This produced the drug product as a fragmented white cake containing cabazitaxel at a weight loading of 1.82%. Example 70 - Feeding 15% cabazitaxel with (Sar175-t>-p-[D-Glu(OBn)25-co-LGlu(OBn)isl) Use the general method of Example 69 with the following exception: the polymer used was poly(Sar)i75-b / oqt / e-pol¡(c / -Glu(OBn)25-co-L-Glu(OBn)25). This produced the pharmaceutical product as a fragmented white cake containing cabazitaxel at a weight loading of 2.22%. Example 71 - Feeding 15% cabazitaxel with TFS-2 (Sari75-ó-p-[D-Leu3o-co-L-Tyr20]) MA / Ί Use the general method of Example 69 with the following exception: the polymer used was TFS-2 (poly(Sar)i75-jb / OQt / e-poly(D-Leu30-co-L-Tyr2o)). This produced the pharmaceutical product as a fragmented white cake containing cabazitaxel at a weight loading of 2.00%. Example 72 - Feeding 15% cabazitaxel with TFS-1 (Sari7s-bp-[D-Leu 35-co-L-Tyr2s] Use the general method of Example 69 with the following exceptions: the polymer used was TFS1 (poly(Sar)i75-t>toqt / e-poly(D-Leu35-co-L-Tyr25)). This produced the pharmaceutical product as a fragmented white cake containing cabazitaxel at a weight loading of 1.84%. Example 73 - Feeding 10% cabazitaxel with TFS-2 (Sari?5-bp-[D-Leu3o-co-L-Tyr2o]) 200 mg of TFS-2 (poly(Sar)i75-b / oque-poly(c / -Leu3o-co-Tyr2o)) was placed in a laboratory beaker equipped with a magnetic stir bar and dissolved in 100 mL of DI water. Separately, cabazitaxel (20 mg) was dissolved in 2 mL of dichloromethane. The aqueous solution was vigorously stirred, and the organic phase was added dropwise over approximately 1 minute. The solution was stirred overnight to allow evaporation of the dichloromethane. The resulting solution was vacuum filtered through a PVDF filter, frozen at -80 °C, and then lyophilized for 2 days. This yielded the pharmaceutical product as a fragmented white cake containing cabazitaxel at a weight loading of 0.77%. Example 74 - Feeding 10% cabazitaxel with TFS-1 (Sari75-bp-[D-Leu35-co-L-Tyr25]) Use the general method of Example 73 with the following exceptions: the polymer used was TFS1 (poly(Sar)i75-t> / oque-poly(D-Leu35-co-L-Tyr25)). This produced the pharmaceutical product as a fragmented white cake containing cabazitaxel at a weight loading of 1.04%. Example 75 - Feeding 5% docetaxel with (Sari25-bp-[D-Leu20-co-L-Tyri5]) 100 mg of poly(Sar)i25-b / oqL / e-poly(d-Leu20-co-Tyri5) and 100 mg of trehalose were dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 10 mg / mL solution of each component. Separately, docetaxel (5 mg) was dissolved in 0.25 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes, frozen at -80 °C, and then lyophilized for 2 days. This yielded the pharmaceutical product as a fragmented white cake containing docetaxel at a weight loading of 2.36%. Example 76 - Feeding 10% docetaxel with (Sari25-bp-[D-Leu20-co-L-Tyri5]) Use the general method of Example 75 with the following exception: The drug solution was prepared by dissolving docetaxel (10 mg) in 0.5 mL of tert-butanol. This produced the pharmaceutical product as a fragmented white cake containing docetaxel at a weight loading of 4.76%. Example 77 - Feeding 15% docetaxel with (Sar125-bp-[D-Leu2o-co-L-Tyri5]) Use the general method of Example 75 with the following exception: The drug solution was prepared by dissolving docetaxel (10 mg) in 0.5 mL of tert-butanol. This produced the pharmaceutical product as a fragmented white cake containing docetaxel at a weight loading of 6.98%.

Claims

1. A multiblock copolymer of Formula I: I wherein: R1a is H or an optionally substituted aliphatic group; R1b is H or an optionally substituted aliphatic group; R2 is H, an optionally substituted aliphatic group or an optionally substituted CO-aliphatic (C1-C6) group; each Ry is independently a D-amino acid side chain; each Rz is independently an L-amino acid side chain; x is 125-350; y is 5-35; z is 5-35.

2. The multiblock copolymer according to claim 1, wherein: each Ry is independently the side chain of y-benzyl-D-glutamate, D-leucine, D-tyrosine, D-phenylalanine, D-alanine, D-valine, D-isoleucine, D-norleucine, O-acetyl-D-tyrosine, Obenzyl-D-tyrosine, or ε-benzyl-D-lysine; and each Rz is independently the side chain of γ-benzyl-L-glutamate, L-leucine, L-tyrosine, L-phenylalanine L-alanine, L-valine, L-isoleucine, L-norleucine, O-acetyl-L-tyrosine, Obenzyl-L-tyrosine, or ε-benzyl-L-lysine.

3. The multiblock copolymer according to claim 1, wherein: each Ry is independently the side chain of γ-benzyl-D-glutamate, D-leucine, D-tyrosine, or D-phenylalanine; and each Rz is independently the side chain of γ-benzyl-L-glutamate, L-leucine, L-tyrosine, or L-phenylalanine 4. The multiblock copolymer according to claim 1, wherein: each Ry is the D-leucine side chain; and each Rz is the L-tyrosine side chain.

5. The multiblock copolymer according to any of claims 1 to 4, wherein R1a is H; R1b is a benzyl, methoxybenzyl, neopentyl, or hexyl group; and R2 is H or COCH3. ML / Ί 6. A multiblock copolymer having the following structure:

7. A multiblock copolymer having the following structure:

8. A multiblock copolymer having the following structure:

9. A multiblock copolymer having the following structure:

10. A multiblock copolymer having the following structure: ML / Ί 11. A multiblock copolymer according to the following structure:

12. A composition comprising a multiblock copolymer according to any of claims 1 to 11 and one or more hydrophobic molecules.

13. The composition according to claim 12, wherein the hydrophobic molecule is present in an amount of approximately 1% by weight to approximately 25% by weight of the composition.

14. The composition according to claim 12 or 13, wherein the hydrophobic molecule is paclitaxel, docetaxel, cabazitaxel or SN-38, or a pharmaceutically acceptable salt of those compounds.

15. The composition according to any of claims 12 to 14, further comprising a cryoprotectant.

16. The composition according to claim 15, wherein the cryoprotectant is glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran or dextrose.

17. The composition according to claim 16, wherein the cryoprotectant is trehalose.

18. The composition according to any of claims 12 to 18, wherein the composition is in the form of a freeze-dried powder.

19. The composition according to any of claims 12 to 18, further comprising a pharmaceutically acceptable carrier.

20. The composition according to claim 19, wherein the vehicle is selected from water, 1,3-butanediol, Ringer's solution, or an isotonic solution of sodium chloride.

21. A method for increasing the solubility of a hydrophobic molecule in an aqueous solution comprising encapsulating the hydrophobic molecule in a multiblock copolymer according to any one of claims 1 to 11.

22. The method according to claim 21, comprising: a. providing the multiblock copolymer in an aqueous solution; b. providing the hydrophobic molecule in an organic solution; c. mixing the aqueous solution and the organic solution to produce an emulsion; d. collecting a supernatant from the emulsion; e. producing a dry powder from the supernatant; and f. solubilizing the dry powder.

23. The method according to claim 22, wherein the aqueous solution and the organic solution are mixed with a homogenizer.

24. The method according to claim 22 or 23, wherein the emulsion is processed using a microfluidizer to produce an extruded solution.

25. The method according to claim 24, further comprising filtering the extruded solution and collecting the supernatant.

26. The method according to any of claims 22 to 25, wherein a cryoprotectant is added to the aqueous solution, the supernatant, or both.

27. The method according to claim 26, wherein the cryoprotectant is glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran or dextrose.

28. The method according to any of claims 22 to 26, wherein the dry powder is produced via lyophilization.

29. The method according to any one of claims 21 to 29, wherein the hydrophobic molecule is paclitaxel, docetaxel, cabazitaxel or SN-38, or a pharmaceutically acceptable salt of those compounds.

30. A method for preparing a composition according to any of claims 12 to 18 comprising: a) dissolving a hydrophobic molecule, a Formula I copolymer and, optionally, a cryoprotectant, in aqueous ferc-butanol, thereby forming a mixed solution; and b) optionally lyophilizing the mixed solution.

31. A method for preparing a composition according to any of claims 12 to 18 comprising: a) dissolving a hydrophobic molecule in ferc-butanol, thereby forming a hydrophobic molecule solution; b) dissolving a copolymer of Formula I and, optionally, a cryoprotectant, in an aqueous solution of ferc-butanol, thereby forming a copolymer solution; c) mixing the hydrophobic molecule solution and the copolymer solution, thereby forming a mixed solution; and d) optionally lyophilizing the mixed solution.

32. A method for preparing a composition according to any of claims 12 to 18 comprising: a) dissolving a hydrophobic molecule in tert-butanol, thereby forming a paclitaxel solution; b) dissolving a Formula I copolymer and, optionally, a cryoprotectant, in an aqueous solution of tert-butanol, thereby forming a copolymer solution; c) mixing the hydrophobic molecule solution and the copolymer solution, thereby forming a mixed solution; d) filtering the mixed solution, thereby forming a filtered solution; e) optionally lyophilizing the filtered solution.

33. A method for preparing a composition according to any of claims 12 to 18 comprising: a. dissolving a hydrophobic molecule, a Formula I copolymer and, optionally, a cryoprotectant, in an aqueous solution, thereby forming a mixed solution; b. processing the mixed solution through a high-shear mixer, thereby forming a high-shear mixer solution; and c. optionally lyophilizing the high-shear mixer solution.

34. A method for preparing a composition according to any one of claims 12 to 18 comprising: a. dissolving a hydrophobic molecule in an organic solvent, thereby forming a hydrophobic molecule solution; b. dissolving a Formula I copolymer and, optionally, a cryoprotectant, in an aqueous solution, thereby forming a copolymer solution; c. mixing the hydrophobic molecule solution and the copolymer solution, thereby forming a mixed solution; d. processing the mixed solution through a high-shear mixer, thereby forming a high-shear mixer solution; and e. optionally lyophilizing the high-shear mixer solution.

35. A method for preparing a composition according to any one of claims 12 to 18 comprising: a. dissolving a hydrophobic molecule in an organic solvent, thereby forming a hydrophobic molecule solution; b. dissolving a Formula I copolymer and, optionally, a cryoprotectant, in an aqueous solution, thereby forming a copolymer solution; c. mixing the hydrophobic molecule solution and the copolymer solution, thereby forming a mixed solution; d. processing the mixed solution through a high-shear mixer, thereby forming a high-shear mixer solution; e. processing the high-shear mixer solution with an MA / Ί diafiltration system, thereby forming a diafiltered solution; f. filtering the diafiltered solution, thereby forming a filtered solution; and g. optionally lyophilizing the filtered solution.